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Abstract: 
According to WHO, iron deficiency anemia is the most common form of malnutrition in 
the world.  Common forms of iron supplement available in the market show low 
bioavailability due to the poor absorption of iron in the GIT, mainly because iron has a 
narrow absorption window in the GIT ―in the upper part of the intestine‖ and because of its 
oxidation in the intestine so decreasing its absorption. Other problems with iron 
supplements include its widespread side effects mainly constipation due to its 
accumulation in the lower GIT. These problems can be solved by using a form of iron that 
is better absorbed, and to maximize the localization of iron at the absorption site at the 
upper part of the GIT. 
The main goal of this study was to formulate a Gastroretentive drug delivery system  
(GRDDS ) of ferrous gluconate, which is intended to stay for a long time period in the 
stomach, meanwhile releasing the iron in a controlled manner to be absorbed in the upper 
part of  the intestine for at least 10 hrs.   
Tablets were prepared by using  swellable polymers having different viscosity properties: 
HPMC k4M, HPMC k15M and HPMC k100Mand ethyl cellulose as a floating enhancer. 
Sodium bicarbonate and citric acid were used as gas generating compounds. Varying 
percentages  of the mentioned excipients  were used and the desired tablets were prepared 
by either wet granulation or direct compression methods. . The choice of the best formula 
manufacturing method was based on the performance of compressed tablet in terms of  
buoyancy and drug release. Floating properties of the tablets, dissolution tests, swelling 
properties and physical properties of tablets; weight variation, friability, hardness were 
done. Physical properties of the powder were also tested, mainly the compressibility index 
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and angle of repose. The kinetics of the release for the chosen formula was elucidated by 
the DDsolver program. 
The effect of polymer viscosity properties on the buoyancy properties were tested ,we 
found that the total floating time is decreased by decreasing the viscosity of swellable 
polymer .  
The results showed that the direct compression method was more suitable in the production 
of a floating tablet which exhibited a sustained release pattern, using the polymer with the 
best viscosity properties HPMC k100M with a finely tuned amount of ethyl cellulose and 
sodium bicarbonate. The formula ―H7‖wich containing HPMC 100 M could allow the 
entrance of enough water to initiate gas generation and floating but at the same time, 
formed a coherent gel that entrapped the gas to from floating and permitted a sustain 
release of  ferrous ions, This chosen formula showed  a floating lag time of 40 seconds and 
total floating time up to 24 hour, with gradual release of ferrous gluconate up to 10 hours.  
All tablet and powder physical properties were in agreement with the official requirements 
of the USP.  
The analysis of the release kinetics showed an agreement with korsemeyer-Peppas model 
of release, which describes the release from swellable polymeric matrices. The swelling 
studies indicated initial swelling of the matrix then erosion. Both the kinetics analysis and 
swelling index analysis may be interpreted by the conclusion that the mechanism of release 
is diffusion coupled by erosion. 
We conclude that such successful GRDDS of iron gluconate  can be helpful in increasing 
the bioavailability of iron. Further in vivo studies on human volunteers are recommended 
in the future. 
 
 
1 
 
 
 
 
 
 
 
 
Part 1 
 
Introduction 
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1. Introduction: 
 
The goal of any drug delivery system is to provide a therapeutic amount of drug to the 
proper site in the body to achieve and maintain therapeutic concentration within range and 
to show pharmacological action with minimum incidence of adverse effects. To achieve 
this goal one should maintain dosing frequency and suitable route of administration [1]. 
There are many kinds of route of administration,  rectal ,nasal, parenteral , topical, vaginal, 
ocular  and the most desired route is the oral route  because of ease of administration, more 
flexibility in designing, ease of production and low cost[2]. 
It is widely acknowledged that the extent of gastrointestinal tract drug absorption is related 
to contact time with the small intestinal mucosa [3]. Control of location of a drug delivery 
system, especially for drugs exhibiting an absorption window in the GI tract or drugs with 
a stability problem, in a specific region of the GI tract offers several advantages. These 
considerations have led to the development of oral controlled-release (CR) dosage forms 
possessing gastric retention capabilities[4].  
Numerous oral delivery systems have been developed to act as drug reservoirs from which 
the active substance can be released over a defined period of time at a predetermined and 
controlled rate. It is evident from the recent scientific and patent literature that there is  an 
increased interest in novel oral controlled release dosage forms that are designed to be 
retained in the upper gastrointestinal tract (GIT) for a prolonged and predictable period of 
time .[5]. 
1.2. Gastro retentive dosage forms: 
Are defined as the forms which are designed to be retained in the gastric region for 
prolonged time and release incorporated drug candidates and thereby enable sustained and 
prolonged input of the drug to the upper part of the GIT thus ensuring its optimal 
bioavailability. [6]. 
This technology has generated enormous attention over the last few decades owing to its 
potential application to improve oral delivery of some important drugs for which prolonged 
gastroretention can greatly improve their oral bioavailability[7] 
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1.2.2-Conventional Oral Dosage forms V.S GRDDS: 
In conventional dosage forms, there is no precise control over the release of drug as the 
administered dose of drug enters the systemic circulation. The minimum effective 
concentration of drug in the blood plasma is not achieved with frequent administration of a 
single dose of a drug because of fluctuations in the plasma drug concentration. As it shows 
in fig(1)  Conventional oral controlled dosage forms suffer from mainly two adversities[8]; 
The short gastric retention time (GRT) and unpredictable gastric emptying time (GET).. 
These problems can be overwhelmed by altering the gastric emptying. Therefore it is 
desirable, to formulate a controlled release dosage form that gives an extended GI 
residence time.[9]. 
Fig (1):Characteristic representation of plasma concentrations of a conventional immediate 
release dosage form, a sustained release dosage form, and an idealized zero-order 
controlled release dosage form [10] 
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Table(1) : Comparison between conventional and Gastroretentive drug delivery system 
[11] 
 
Gastro retentive drug delivery system Conventional drug delivery system 
Less side effect More side effect 
Improves patient compliance as drug is taken 
once daily  
Patient compliance is less due to Taking medication 
frequently during the day 
 . 
Improve gastric retention time Less gastric retention time 
Appropriate for delivery of drugs with 
narrow  absorption window in small 
Intestinal region 
Not appropriate for delivery of drugs with narrow 
absorption window in small intestine region. 
Beneficial for drugs exhibit local action in the 
stomach . 
 
Not much beneficial for drugs Exhibit local action in 
the stomach.  
 
 Suitable for drugs that degrade in the colon . 
 
Not suitable for Drugs that Degrade in the colon . 
 
Suitable for drugs having rapid absorption 
through GIT   
Not suitable for drugs having rapid absorption through 
GIT 
High risk of dose dumping. No risk of dose dumping 
 
1.2.3 The types of GRDDS: 
Gastroretentive can be achieved by  physiological, pharmacological and pharmaceutical 
method :[12] 
The Physiological approach: Uses  natural materials or fat derivatives such as 
Triethanolamine myristate which stimulate the duodenal receptors to slow gastric 
emptying. 
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Or the use of large amounts of volume filling polymer such Polycarbophil will also slow 
gastric emptying. The Pharmacological approach: It involves the co administration or 
incorporation of a drug for delaying gastric emptying e.g. Loperamide. 
The previous  approaches are not used because of toxicity problem while -Pharmaceutical 
approach :are delivery systems which designed to be retained in the stomach for extended 
time periods these system includes many types and forms as listed below and as it shows in 
figure (2):[9] 
1. Low Density systems/Floating Dosage Forms 
A. Effervescent Systems/Gas Generating Systems: 
1) Volatile Liquid Containing System. 
2) Gas Generating System . 
3) Floating Film Delivery System . 
B. Non-Effervescent Systems: 
1- Hydrodynamically Balanced  System . 
2-Microballons/hallow Microsphere System . 
3-Intragastric FDDS. 
4-Swelling or Expanding System. 
5-Alginate Beads System .   
2. High Density Systems 
3.MucoadhesiveSystems   
4.SuperporousHydrogels Systems. 
 5. Magnetic Systems 
6. Raft Floating System: 
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Fig(2)Types of GRDDS[9] 
 
 
 
1.2.3.1-Low density systems/Floating dosage forms:[13] 
 
Floating drug delivery systems is one of the important approaches to achieve gastric 
retention to obtain sufficient drug bioavailability. These Delivery Systems are desirable for 
drugs with an absorption window in the stomach or in the upper small intestine. This type 
of delivery system is of great value for drugs which get absorbed from upper part of the 
stomach .[14]. 
These systems have a bulk density less then gastric fluids and so remain buoyant in the 
stomach without affecting gastric emptying rate for a prolonged time periods and the drug 
is released slowly from the system. After release of drug, the residual system is emptied 
from the stomach. This result in an increased gastric retention time (GRT) and a better 
control of the fluctuation in plasma drug concentration 
The major requirements for a floating drug delivery system are:  It should release contents 
slowly to serve as a reservoir. It must maintain specific gravity lower than gastric contents 
(1.004 – 1.01 gm/cm3).and  It must form a cohesive gel barrier.   
a). Effervescent Systems/Gas Generating Systems : 
A drug delivery system can be made to float in the stomach by incorporating a floatation 
chamber, which may be filled with vacuum, air or inert gas. The gas in the floatation 
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chamber can be introduced either by the volatilization of an organic solvent or by the 
effervescent reaction between organic acids and bicarbonate salts. [9] 
1) Volatile Liquid Containing Systems: These have an inflatable chamber which contains 
a liquid e.g. Ether, Cyclopentane, that gasifies at body temperature to cause the inflation of 
the chamber in the stomach .as it shows in figure(3) These systems are somatically 
controlled floating systems containing a hollow deformable unit. There are two chambers 
in the system first contains the drug and the second chamber contains the volatile 
liquid[15] 
Fig (3)Volatile Liquid Containing Gastro retentive System 
 
 
[16] 
 
2)Gas Generating Systems:  These buoyant delivery systems utilizes effervescent reaction 
between carbonate/bicarbonate salts and citric/tartaric acid to liberate CO2 , which gets 
entrapped in the jellified hydrocolloid layer of the system, thus decreasing its specific 
gravity and making it float as it shows in figure (4)  .  
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Fig (4) Gas generating Floating Drug Delivery System 
 
 
[13] 
 
A multiple unit type of floating pills, which generate CO2, have also been developed. The 
system consists of a sustained release (SR) pill as seed, surrounded by double layers. The 
inner layer is an effervescent layer containing sodium bicarbonate and tartaric acid. The 
outer layer is of a swell able membrane layer.[15] 
3) Floating Film Delivery System: A drug loaded thin filmstrip filled into capsule is 
typically designed for oral drug delivery. Floating film offers advantages as, preparation of 
film is very simple, time saving, economically beneficial and chances of cross 
contamination are very low, also handling of film is very easy as compared with 
microspheres.  
b). Non-Effervescent Systems: 
Non-effervescent floating drug delivery systems are normally prepared from gel-forming 
or highly swellable cellulose type hydrocolloids, polysaccharides or matrix forming 
polymers. In one approach, intimate mixing of drug with a gel forming hydrocolloid which 
results in contact with gastric fluid after oral administration and maintain a relative 
integrity of shape and a bulk density less than unity within the gastric environment. The air 
trapped by the swollen polymer confers buoyancy to these dosage forms. Excipients most 
commonly used  in these systems include hydroxypropyl methylcellulose (HPMC) 
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polyacrylates, polyvinyl acetate, carbopol, agar, sodium alginate, calcium chloride, 
polyethylene oxide and polycarbonates .[13] 
 This system can be further divided into the flowing sub-types: 
1. HydrodynamicallyBalanced Systems:  The polymer is mixed with drugs and usually 
administered in hydrodynamically balanced system capsule. The capsule shell dissolves in 
contact with water and mixture swells to form a gelatinous barrier, which imparts 
buoyancy to dosage form in gastric juice for a long period as it shows in figure (5). 
Because, continuous erosion of the surface allows water penetration to the inner layers 
maintaining surface hydration and buoyancy to dosage form. [13] 
 
Fig (5) Hydro-dynamically Balanced System 
 
[13] 
 
2. Microballoons / Hollow microspheres: is loaded with drugs ,prepared by simple 
solvent evaporation or solvent diffusion/evaporation methods as it shows in figure (6)  to 
prolong the gastric retention time (GRT) of the dosage form. 
 Commonly used polymers to develop these systems are polycarbonate, cellulose acetate, 
calcium alginate, Eudragit S, agar and low methoxylated pectin etc. Buoyancy and drug 
release from dosage form are dependent on quantity of polymers, the plasticizer polymer 
ratio and the solvent used for formulation.  
The microballoons floats continuously over the surface of an acidic dissolution media 
containing surfactant for >12 hours .[13, 17] 
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Fig (6)Microballoons / Hollow microspheres drug delivery system[13] 
 
 
 
 
.3- Intragastric FDDS: the drug reservoir is encapsulated inside a micro porous 
compartment with halls along its top and bottom walls as it show in figure (7). The 
peripheral walls of the drug reservoir compartment are completely sealed to prevent any 
direct contact of the stomach mucosal surface with the undissolved drug. In the stomach, 
the floatation chamber causes it to float in the gastric fluid. Fluids enter through the  halls , 
dissolve the drug, and carry the drug solutes out from the delivery system for continuous 
transport to the intestine for absorption[9]. 
 
Fig (7) Intra Gastric Floating Gastrointestinal Drug Delivery Device[18] 
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4) Swelling or Expanding Systems: 
If a dosage form is bigger than the pyloric sphincter it will withstand the gastric transit. But 
the dosage form must be small to be swallowed. 
 There are three configuration features required: 
1-A small size for swallowing, 
2-An expanded form for gastroretention 
3-Finally a small form for evacuation[14] 
After swallowing these systems swell to an extent that prevents their exit from the stomach 
through the pylorus. As it show in figure (8) These systems are also called as ―Plug type 
systems‖, since they have tendency to remain logged at the pyloric sphincter[19] 
 When polymers come in contact with gastric fluid, the polymer imbibes water and swells. 
The swelling of these polymers is due to presence of physical‐chemical cross links in the 
hydrophilic polymer network.[20] 
 
 
Fig (8)Swelling (Expandable) Drug Delivery System[11] 
 
 
 
 
 
 
 
 
 
5)Alginate Beads System:  Multi-unit floating dosage forms have been developed from 
freeze-dried calcium alginate. Spherical beads of approximately 2.5 mm in diameter can be 
prepared by dropping sodium alginate solution into aqueous solution of calcium chloride, 
causing the precipitation of calcium alginate as it shows in figure (9). The beads are then 
separated, snap-frozen in liquid nitrogen, and freeze-dried at -40C
◦
for 24 h, leading to the 
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formation of a porous system, which can maintain a floating force for over 12 h. These 
floating beads gave a prolonged residence time of more than 5.5 hours.[9] 
Fig (9) the formulation process of Na alginate drug delivery system[21] 
 
1.2.3.2 High Density Systems: 
 
These systems have density higher than the stomach fluid (1.004 g/cm
3
). It would be at 
least 1.50 g/cm
3
[22] 
These systems are able to withstand peristaltic movement and retained in the stomach in 
the Pyloric Antrum for several hours[20] These systems can be manufacture by coating the 
drug with a heavy inert  material such as barium sulphate, zinc oxide, titanium  dioxide, 
iron powder[19] but this system has major drawback that has many technical problems, 
and cannot stand the vigorous and continuous contraction of the stomach leading to high 
probability to be evacuated from the stomach rabidly . 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
 Fig(10) High Density Drug Delivery System [17] 
 
 
1.2.3.3MucoadhesiveSystems: 
 
Bioadhesive drug delivery systems are used to localize a delivery device within the human 
to enhance the drug absorption in a site-specific manner as it shows in figure ( 11). In this 
approach, various Bioadhesive polymers are used and they can adhere to the epithelial 
surface in the stomach[23] .They increase the GRT of the dosage forms.  The basis of 
micro adhesion is that a dosage form can stick to the mucosal surface by different 
mechanisms that can be summarized :[24, 25].In the wetting theory, which is based on the 
ability of Bioadhesive polymers to spread and develop intimate contact with the mucous 
layers. Or the diffusion theory, which proposes physical entanglement of mucin strands 
with the flexible polymer chains, or an interpenetration of mucin strands into the porous 
structure of the polymer substrate. Or   the absorption theory, suggests that bioa-dhesion is 
due to secondary forces such as Vander Waal forces and hydrogen bonding. And. The 
electron theory, which proposes attractive electrostatic forces between the glycoprotein 
mucin network and the bio adhesive material. 
 
 Major drawback  of this system is gastric muco adhesion does not tend to be strong 
enough to impart to dosage forms the ability to resist the strong contraction  forces of the 
stomach wall 
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Fig (11) Muco adhesive Drug Delivery System[13] 
 
 
 
1.2.3.4 Super-porous Hydro-gels : 
Super porous hydro gels, With an  average pore of size less than 100 µm, swell to 
equilibrium size within a minute, due to rapid water uptake by capillary wetting through 
numerous interconnected open pores[26].  
Super-porous hydro-gels must possess following properties in order to act as gastric 
retention device, Initial size should be small enough for easy swallowing. The  Swelling 
should be fast enough to overcome gastric emptying. The  Size of swollen hydro gel should 
be large enough to be retained in the stomach. And the Swollen hydro gel should be strong 
enough to withstand contraction pressure, abrasion   and shear forces in stomach. 
Among a number of polymers tested, polyanions with a high charge density are highly 
recommended  .[9]. 
 
1.2.3.5Magnetic systems: 
This approach to enhance the GRT is based on the simple principle that the dosage form 
contains a small internal magnet like (ultra-fine ferrite (ã-Fe2O3)),[5] and a magnet placed 
on the abdomen over the position of the stomach. Although magnetic system seems to 
work, the external magnet must be positioned with a degree of precision that might 
compromise patient compliance[5] 
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1.2.3.6 Raft Floating System: 
Raft forming systems incorporates alginate gels[27].The mechanism involved in the raft 
formation includes the formation of viscous cohesive gel in contact with gastric fluids as it 
shows in figure (12), where in each portion of the liquid swells forming a continuous layer 
called a raft .This raft floats on gastric fluids because of low bulk density created by the 
formation of CO2. A patent assigned to Reckitt and Colman Products Ltd., describes the 
treatment of Helicobacter pylori (H. Pylori) infections in the GIT a raft forming 
formulation.   [28] 
Fig (12) raft floating drug delivery system[29] 
 
 
 
 
 
 
 
 
 
1.3 Advantages of Gastro retentive Drug Delivery System: 
Extended release dosage form with prolonged residence time in stomach is highly desirable 
for drugs that are: locally active in stomach, have an absorption window  in the stomach or 
in the upper small intestine, which are unstable in the intestinal or colonic environment or 
which have low solubility at high pH values[19, 30] 
Advantages of GRDDS can be summarized as:[12] 
1). Avoiding patient compliance problems by reducing the frequency administration time 
of the tablets to once daily .  
 2). Patients use less dose of drug: so this help in  
  i) Minimize or eliminate local side effects hence they are useful in the treatment of 
disorders related to stomach and small intestine (e.g. eradication of Helicobacter pylori). 
Gastric fluid  
Raft  forming  gel  
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 ii) Minimize or eliminate systemic side effects thus minimizing or eliminating systemic 
exposure of drugs. This site-specific drug delivery reduces undesirable effects of side 
effects.  
 iii) Obtain less potentiating or reduction in drug activity with chronic use.   
iv) Minimize drug accumulation with chronic dosing. 
 3.) The Gastroretentive systems are advantageous for drugs absorbed through the stomach. 
e.g. Ferrous salts, antacids and the reduction of  fluctuation in drug level.[2],. 
4.) Reduced fluctuation of drug concentrations: Continuous input of the drug following 
controlled release Gastroretentive delivery produces systemic drug concentrations within a 
narrower range compared to the immediate release oral dosage forms. Thus, fluctuations in 
drug effects are minimized and concentration dependent side effects that are associated 
with peak concentrations can be prevented. 
 5.) When there is a vigorous intestinal movement and a short transit time as might occur in 
certain type of diarrhea, poor absorption is expected. Under such circumstances it may be 
advantageous to keep the drug in floating condition in stomach to get a relatively better 
response[2] 
1.4 List of marketed floating dosage form:[31, 32] 
Table(2) list of marketed dosage form 
Brand name AP
I 
Dosageform Company/country 
Modapar® Levodopa, benserazide Floating controlled release capsule RocheProducts/USA 
Prolopa® Levodopa, benserazide Floating controlled release capsule RocheProducts/USA 
Valrelease® Diazepam Floating capsule Hoffmann-LaRoche/USA 
Liquid 
Gavison 
Aluminiumhydroxide, 
Magnesiumcarbonate 
Effervescentfloatingliquid alginate 
preparation 
GlaxoSmithKline/INDIA 
Topalkan® Aluminium-Magnesium 
antacid 
Floatingliquid alginatepreparation PierreFabre 
Drug/FRANCE 
AlmagateFlatc
oat 
Aluminium-Magnesium 
antacid 
Floatingdosage form PierreFabre 
Drug/FRANCE 
Conviron® Ferrous sulfate Colloidal gel formingFDDS Ranbaxy/INDIA 
Cifran® Ciprofloxacin Gas-generatingfloatingtablets Ranbaxy/INDIA 
Oflin OD Ofloxacin Gas-generatingfloatingtablets Ranbaxy/INDIA 
Cytotec® Misoprostal Bilayerfloating capsule Pharmacia/USA 
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1.5  Ideal Drug Candidates For GastroRetentive Drug Delivery System:[13] 
 In general, appropriate candidates for CRGRDF are molecules that have poor colonic or 
lower small intestine  absorption but are characterized by better absorption properties at the 
upper parts of the GIT: 
1) Narrow absorption window in GItract, e.g., riboflavin and levodopa 
2) Primarily absorbed from stomach and upper part of GItract, e.g., calcium supplements, 
chlordiazepoxide , cinnarazine and ferrouse salts   
3) Drugs that act locally in the stomach, e.g., antacids , misoprostol and drug treat H.pylori  
4) Drugs that degrade in the colon, e.g., ranitidine HCl and metronidazole  
5) Drugs that disturb normal colonic bacteria, e.g., amoxicillin trihydrate 
6) Drugs that have efflux pumbes in the lower intestin . 
1.6Drugs those are unsuitable for Gastroretentive Drug Delivery Systems:[13] 
 1. Drugs that have very limited acid solubility e.g. phenytoin. 
 2. Drugs that suffer instability in the gastric environment e.g. erythromycin. 
 3. Drugs intended for selective release in the colon e.g. 5- amino salicylic acid and 
corticosteroids etc. 
1.7   Factors affecting GastricRetention: 
1.7.1 Physiological factors: 
 Size of dosage form: Dosage forms having diameter greater than the diameter of pyloric 
sphincter escape from gastric emptying and remain within gastric region[16]. Dosage form 
units with a diameter of more than 9.5mm are reported to have an increased GRT[33] 
 Shape of dosage form: Round or Ring shaped dosage form are considered better in 
comparison to other shapes.[16] 
 Density: Location of the particular gastro retentive dosage form in gastric region 
depends on density of the system. Those with low density tend to float on the gastric fluid 
surface while high density systems sink to bottom of stomach.[16] 
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1.7.2 Biological Factors: : 
 Age: Geriatric patients show a longer gastric retention time, while the neonates and 
children have low gastric retention time, in comparison to a normal adult.[16] Elderly 
people, especially those over 70 years old, have a significantly longer GRT[15] 
 Gender: Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with their 
age and race-matched female counterparts (4.6±1.2 hours), regardless of the weight, height 
and body surface[15] 
 Caloric content : GRT can be increased by four to ten hours with a meal that is high in 
proteins and fats[15] 
 Fed or Unfed state:Under fasting conditions, the GI motility is characterized by periods 
of strong motor activity or the migrating myoelectric complex (MMC) that occurs every 
1.5 to 2 hours. The MMC sweeps undigested material from the stomach and, if the timing 
of administration of the formulation coincides with that of the MMC, the GRT of the unit 
can be expected to be very short. However, in the fed state, MMC is delayed and GRT is 
considerably longer[15] 
 Feed frequency: The gastric retension time can be increased by over 400 minutes when 
a successive meals are given compared with a single meal due to the low frequency of the 
migrating myoelectric complex( MMC)[15]. 
 :Nature of meal – Feeding of indigestible polymers or fatty acid salts can change the 
motility pattern of the stomach to a fed state, thus decreasing the gastric emptying rate and 
prolonging drug release[15]. 
 Posture :[34] conducted  a comparative study in humans, the floating and non-floating 
systems behaved differently in the upright position, the floating systems floated to the top 
of the gastric contents and remained for a longer time, showing prolonged GRT. But the 
non-floating units settled to the lower part of the stomach and underwent faster emptying 
as a result of peristaltic contractions, and the floating units remaineaway from the pylorus 
region . 
 Concomitant drug administration: Administration of certain drugs along with gastric 
motility enhancers (metoclopramide, cisapride) or depressants (atropine), greatly affect 
gastric retention time and hence absorption of stomach specific absorbing drugs[16] 
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 Disease state: Gastro retentive time is altered during the various gastric diseases like 
Crohn’s disease etc.[16] 
1.8  Disadvantages of GDDS:[35] 
1). Gastric retention is influenced by many factors such as gastric motility, pH and 
presence of food, and mucus turnover. These factors are never constant and hence the 
buoyancy cannot be predicted. 
 2.) Drugs that cause irritation and lesion to gastric mucosa are not suitable to be 
formulated as floating drug delivery systems. 
1.9 Drawbacks of the gastro retntive drug deivery systems:[36] 
Table (3) drawbacks of gastro retentive drug delivery system 
Drawbacks Technology 
Cannot be manufactured with large amount of drug due to technical 
problems. Till date no such system is available in the market. 
High density systems 
Highly depends on the fed state of stomach; higher level of fluid is required 
in gastric region 
Floating systems 
Storage troubles due to hydrolysable, biodegradable polymers. Difficult to 
manufacture and not economical. 
Expandable systems 
Efficiency can be reduced in rapid turnover of mucus. Might bind to other 
mucosal lining like esophagus 
Mucoadhesive 
systems 
Might compromise with patient compliance. Magnetic systems 
 
 
1.10 Anatomy and physiology of the stomach and a description of gastric emptying: 
The stomach is an expanded section of the digestive tube between the esophagus and small 
intestine. The wall of the stomach is structurally similar to the other parts of the digestive 
tube, with the exception that stomach has an extra, oblique layer of smooth muscle inside 
the circular layer, which aids in the performance of complex grinding motions. In the 
empty state, the stomach is contracted and its mucosa and sub-mucosa are thrown up into 
distinct folds called Rugae.[15]. 
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Fig (13) The Anatomy of the Human Stomach[37] 
 
 
 
 
 
 
 
 
1.10.1 Gastric Motility: 
 Gastric motility is controlled by a complex set of neural and hormonal signals. Nervous 
control originates from the enteric nervous system as well as parasympathetic 
(predominantly Vagus nerve) and sympathetic systems. A large battery of hormones has 
been shown to influence gastric motility ;both gastrin and Cholecystokinin act to relax the 
proximal stomach and enhance contractions in the distal stomach. The bottom line is that 
the patterns of gastric motility likely are a result from smooth muscle cells integrating a 
large number of inhibitory and stimulatory signals. Liquid readily passes through the 
pylorus in spurts, but solids must be reduced to a diameter of less than 1-2 mm before 
passing the pyloric gatekeeper. The gastric volume is important for dissolution of the 
dosage form in vivo. The resting volume of the stomach is 25-50 ml.The pH of fasting 
stomach is 1.2-.2.0 and in fed conditions 2.0-6.0.[38] 
1.10.2 Gastric Emptying Rate: 
 Gastric emptying occurs during fasting as well as fed states. The pattern of motility is 
however distinct in the 2 states. During the fasting state an interdigestive series of 
electrical events take place, which cycle both through stomach and intestine every 2 to 3 
hours. This is called the inter digestive mylo electric cycle or migrating mylo electric cycle 
(MMC), which is further divided into following 4 phases as described by Wilson and 
Washington.[39] 
1.) Phase I (Basal phase): lasts from 40 to 60 minutes with rare contractions.   
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2.) Phase II (Pre burst phase): lasts for 40 to 60 minutes with intermittent action potential 
and contractions. As the phase progresses the intensity and frequency also increases 
gradually.  
 3.) Phase III (burst phase): lasts for 4 to 6 minutes. It includes intense and regular 
contractions for short period. It is due to this wave that all the undigested material is swept 
out of the stomach down to the small intestine. It is also known as the housekeeper wave.  
 4.) Phase IV: lasts for 0 to 5 minutes and occur between phases III and I of 2 consecutive 
cycles.   
After the ingestion of a mixed meal, the pattern of contractions changes from fasted to that 
of fed state. This is also known as digestive motility pattern and comprises continuous 
contractions as in phase II of fasted state. These contractions result in reducing the size of 
food particles (to less than 1 mm), which are propelled toward the pylorus in a suspension 
form. During the fed state onset of MMC is delayed resulting in slowdown of gastric 
emptying rate.[40] 
Major  studies determining gastric emptying rates revealed that orally administered 
controlled release dosage forms are subjected to basically 2 complications, that of short 
gastric residence time and unpredictable gastric emptying rate. 
1.11 Introductions on Iron: 
Iron is a mineral that can be found in plants, animals, soil, air, water, and rocks. 
But iron is also an essential micronutrient.   This means that the body does not produce the 
nutrient; it has to be gotten from food. Micronutrient means that the body only requires 
tiny amounts of it to function normally. [41] 
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1.11.1 Dietary Iron: 
Iron is present in Diets 10% to 15% Heme iron (from meat) and 85% to 90% Nonheme 
iron (from meat and plant sources). The bioavailability of iron, which is the amount of iron 
present in food that is absorbed, is lower for non hemeiron than for heme iron. (Food and 
Administration 2001) 
 
Nonheme dietary iron requires the acidic environment of the stomach to be solubilized. 
Absorption of nonheme iron is inhibited when gastric pH is increased and when iron forms 
insoluble complexes with compounds found in plants, such as phytates and polyphenols. 
The bioavailability of nonheme iron also will be reduced in the presence of other minerals 
such as zinc and calcium. The bioavailability of nonheme iron from a mixed diet is 
decreased twofold by the presence of these inhibitors.  
 
Ascorbic acid (vitamin C) and other organic acids increase nonheme iron absorption. 
Absorption of heme iron occurs via a mechanism independent of that for nonheme iron. 
The bioavailability of heme iron is about 25%; that of nonheme iron varies from 10%-5%  
in a mixed diet . The estimated overall bioavailability of iron from a typical  diet is 
18%[42]. 
The estimated average requirement and recommended dietary allowance of iron for adult 
men and women is summarized in the following table (4) in which:  
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Table (4) the Estimated Average Requirement and Recommended Dietary Allowance of 
Iron for Adult Men and Women 
 
UL(mg) RDA(mg) EAR(mg)  
 
45 
45 
45 
45 
 
8 
8 
8 
8 
 
6 
6 
6 
6 
Men, age (year) 
19-30 
31-50 
50-70 
>70 
 
 
 
 
45 
45 
45 
45 
 
 
 
 
 
18 
18 
8 
8 
 
 
 
 
8.1 
8.1 
5 
5 
 
Women  
Nonpregnant 
Non lactating  
Age (year) 
19-30 
31-50 
50-70 
>70 
 
 
45 
45 
 
27 
27 
 
22 
22 
Pregnant age(years) 
19-30 
31-50 
 
45 
45 
 
9 
9 
 
6.5 
6.5 
Lactating Age(year) 
19-30 
30-50 
EAR: means estimated average requirement  
RDA: means recommended dietary allowance 
UL: means upper tolerable level. [42] 
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1.11.2 Iron absorption: 
 
The digestive system is set up to maximize absorption; there is no regulation of the 
amounts of substances absorbed into the body. A notable exception is iron, in which daily 
dietary absorption is regulated so that it matches daily iron loss. 
 The reason that absorption must be carefully regulated is that the body does not possess a 
physiological mechanism for regularly eliminating iron from the body. 
Iron plays a dichotomous role in almost all living organisms as it possesses features of both 
an essential nutrient and a potential toxin [43, 44]. Iron is a central component of vital 
proteins such as the enzymes involved in deoxy nucleotide synthesis, the citric acid cycle, 
drug metabolism and mitochondrial electron transport [45]. Among all the iron-containing 
proteins, hemoglobin, the oxygen transport molecule in circulating red blood cells (RBCs), 
is the one most abundantly expressed. Consequently, absolute or functional iron deficiency 
(ID) is associated with insufficient availability of iron for hemoglobin synthesis and thus 
results in anemia.  However, too much iron in the body can be extremely toxic to tissues 
because it promotes the formation of free radicals[46]. 
Fig (14) iron absorption and metabolism[47] 
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Iron is a trace mineral that plays essential roles in the human system. Two thirds of the iron 
inside the body is found within hemoglobin which is  an iron-containing protein found in 
red blood cells that carries oxygen[48].The remaining iron is located in myoglobin, which 
assists in the storage and transport of oxygen within muscles[48]. The remaining iron, a 
significant portion is stored in the liver, both in the hepatocytes, and in the Kupffer cells 
(also known as Reticuloendothelial cells), a type of macrophage found in the liver. Kupffer 
cells play an important role in recycling body iron. They ingest aged red blood cells, 
liberating iron for reuse by breaking down hemoglobin[46]. 
 
There is some controversy even among health professionals regarding ―normal‖ 
hemoglobin concentrations, but the generally accepted ranges for adults are 12-16 g/dl for 
women and 13.5 - 18 g/dl for men[49].Anemia is the condition associated with hemoglobin 
concentrations below the defined normal range. Because :All body cells need iron. It is 
crucial for oxygen transport, energy production, and cellular growth and proliferation. The 
human body contains an average of 3.5 g of iron (males 4 g, females 3 g). and only about 
10% of dietary iron is absorbed (1–2 mg/day) Individuals absorb less than 10% of dietary 
iron, or 1–2 mg per day balancing the daily loss from desquamation of epithelia .Most 
absorbed iron is used in bone marrow for Erythropoiesis Iron homeostasis is closely 
regulated via intestinal absorption. So once iron is absorbed, there is no physiologic 
mechanism for excretion of excess iron from the body other than blood loss (i.e., 
pregnancy, menstruation or other bleeding.).[47] 
Hence, maintenance of systemic iron balance requires tight control of intestinal iron 
absorption since there is apparently no regulated mechanism for hepatic or renal excretion 
of iron in mammals. Gastrointestinal absorption of iron occurs in the duodenum and 
proximal jejunum as it shows in figure (15) where this essential nutrient is taken up in two 
forms: as heme iron from the digestive breakdown of hemoglobin and myoglobin 
contained in red meat, poultry and fish and as inorganic non-heme iron mainly released 
from vegetarian food [50]. Approximately 15–35% of dietary heme available in the 
intestinal lumen is absorbed via HCP1( Heme Carrier Protein 1) and heme is then degraded 
to ferrous iron, carbon monoxide and the bile pigment biliverdin by HO1 (Heme 
Oxygenase 1)[51]. Inorganic iron is absorbed by 2–20% of the amount initially ingested 
with food and occurs in two redox states, its ferric and ferrous forms. 
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Fig (15)  Iron Absorption Mechanism 
 
 
Where: DMT1 : Divalent metal transporter 1/ HEME OX : Heme oxygenase 1 enzyme /  
TFR-HFE: Trans ferrin receptor  
Iron is absorbed by villous enterocytes in the proximal duodenum. Efficient absorption 
requires an acidic environment, and antacids or other conditions that interfere with gastric 
acid secretion can interfere with iron absorption.  
Ferric iron (Fe
+3
) in the duodenal lumen is reduced to its ferrous form(Fe
+2
) through the 
action of a brush border ferri reductase enzyme. Iron is co-transported with a proton into 
the enterocyte via the divalent metal transporter DMT-1. This transporter is not specific for 
iron, but also transports many divalent metal ions.  
Once inside the enterocyte, iron follows one of two major pathways. Which path is taken 
depends on a complex programming of the cell based on both dietary and systemic iron 
loads:  
 Iron abundance states: iron within the enterocyte is trapped by incorporation into ferritin 
and hence, not transported into blood. When the enterocyte dies and is shed, this iron is 
lost. A single ferritin molecule can store up to 4,000 iron atoms. When excess dietary iron 
is absorbed, the body responds by producing more ferritin to facilitate iron storage. 
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 Iron limiting states: iron is exported out of the enterocyte via a transporter (ferroportin) 
located in the basolateral membrane. It then binds to the iron-carrier transferrin for 
transport throughout the body.  
 Iron in the form of heme, from ingestion of hemoglobin or myoglobin, is also readily 
absorbed. In this case, it appears that intact heme is taking up by the small intestinal 
enterocyte by endocytosis. Once inside the enterocyte, iron is liberated and essentially 
follows the same pathway for export as absorbed inorganic iron. Some heme may be 
transported intact into the circulation. [52, 53] 
1.11.3 Anemia and Iron Deficiency Anemia: 
1.11.3.1 Anemia: 
Is a condition in which the number of red blood cells or their oxygen-carrying capacity is 
insufficient to meet physiologic needs which vary by age, sex, smoking, and pregnancy 
status.  
Iron deficiency is thought to be the most common cause of anemia globally, although other 
conditions, such as folate, vitamin B12 and vitamin A deficiencies, chronic inflammation, 
parasitic infections, and inherited disorders can all causes anemia. In its severe form, it is 
associated with fatigue, weakness, dizziness and drowsiness [54]. 
Iron deficiency anemia is a common type of anemia — a condition in which blood lacks 
adequate healthy red blood cells. Red blood cells carry oxygen to the body's tissues., Iron 
deficiency anemia is due to insufficient iron. Without enough iron, the body can't produce 
enough of a substance in red blood cells that enables them to carry oxygen (hemoglobin). 
As a result, iron deficiency anemia causes  tiredness and short of breath[55]. 
1.11.3.2 Diagnosis of anemia. 
The definition of anemia varies by sex and age. The most commonly used definitions of 
anemia come from the World Health Organization (WHO) as it shows in table (5)  
  
 
 
28 
 
Table  (5) definition of anemia according to hemoglobin level : [56] 
Minimum Hemoglobin levels used to define 
anemia  
Hemoglobin 
(g/dl) 
Age or sex group 
11 Children 6 months to 6 
years 
11.5 Children 5-11years 
12 Children 12-13 years 
12 Non-pregnant women  
11 Pregnant women   
13  Men  
From WHO/UNICEF 
 
 
Iron deficiency results when iron demand by the body is not met by iron absorption from 
the diet.,[57] 
1.11.3.3 Causes of Iron Deficiency: 
The daily iron requirement for adolescent girls and premenopausal women is 
approximately 20 mg elemental iron. However, this amount often is not attained because 
absorption from dietary sources is limited by the absorptive capacity of the intestine [58]. 
Major causes are: 
1- ) Pregnancy or Blood Loss Due to Menstruation: 
In women of child-bearing age, the most common causes of iron-deficiency anemia are 
heavy menstrual bleeding or blood loss during childbirth. The CDC found that about nine 
percent of women ages 12 to 49 years are deficient in iron .[59] 
2- ) Internal Bleeding: 
Including ulcer in the stomach, polyps (tissue growths) in the colon or intestines, or colon 
cancer. Regular use of pain relievers, such as aspirin, can also cause bleeding in the 
stomach[60] 
 
3- ) Inability to Absorb Iron: 
Certain disorders or surgeries that affect the intestines can also interfere with how the body 
absorbs iron. Celiac disease or an intestinal surgery such as gastric bypass may limit the 
amount of iron your body can absorb.[60]. 
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1.11.3.4 people at Risk for Iron-Deficiency Anemia[61] 
1) Young children who drink a lot of cow's milk may be at risk for iron-deficiency anemia. 
Milk is low in iron, and too much milk may take the place of iron-rich foods in the diet. 
Too much milk also may prevent children's bodies from absorbing iron from other food as 
the calcium is also absorbed by the same receptor. 
2) Teens are at risk for iron-deficiency anemia if they're underweight or have chronic 
(ongoing) illnesses.. 
3) Women of childbearing age are at higher risk for iron-deficiency anemia because of 
blood loss during their monthly periods. About 1 in 5 women of childbearing age has iron-
deficiency anemia.  [61] 
Pregnant women also are at higher risk for the condition because they need twice as much 
iron as usual. The extra iron is needed for increased blood volume and for the fetus' 
growth. 
About half of all pregnant women develop iron-deficiency anemia.  [61] 
4) Adults who have internal bleeding, such as intestinal bleeding, can develop iron-
deficiency anemia due to blood loss. Certain conditions, such as colon cancer and bleeding 
ulcers, can cause blood loss. Some medicines, such as aspirin, also can cause internal 
bleeding. 
5) People who get kidney dialysis treatment may develop iron-deficiency anemia. This is 
because blood is lost during dialysis.  
6) People who have gastric bypass surgery also may develop iron-deficiency anemia. This 
type of surgery can prevent the body from absorbing enough iron. 
1.11.3.5 Signs and Symptoms of Anemia 
The most common symptom of all types of anemia is fatigue (tiredness). Fatigue occurs 
because the body doesn't have enough red blood cells to carry oxygen to its parts. Anemia 
also can cause shortness of breath, dizziness, headache, coldness in your hands and feet, 
pale skin, chest pain, weakness, and fatigue (tiredness).Low limits of hemoglobin-carrying 
red blood cells, can lead to irregular heartbeat called arrhythmias, a heart murmur, an 
enlarged heart, or even heart failure. In infants and young children, signs of anemia include 
poor appetite, slowed growth and development, and behavioral problems.[61] 
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1.11.3.6 Signs and Symptoms of Iron Deficiency. 
Signs and symptoms of iron deficiency may include brittle nails, swelling or soreness of 
the tongue, cracks in the sides of the mouth, an enlarged spleen, and frequent infections. 
People who have iron-deficiency anemia may have an unusual craving for nonfood items, 
such as ice, dirt, paint, or starch. This craving is called pica (PI-ka or PE-ka). 
Some people who have iron-deficiency anemia develop restless legs syndrome (RLS). RLS 
is a disorder that causes a strong urge to move the legs. This urge to move often occurs 
with strange and unpleasant feelings in the legs. People who have RLS often have a hard 
time sleeping. 
Iron-deficiency anemia can put children at greater risk for infections. Some signs and 
symptoms of iron-deficiency anemia are related to the condition's causes. For example, a 
sign of intestinal bleeding is bright red blood in the stools or black, tarry-looking stools. 
Very heavy menstrual bleeding, long periods, or other vaginal bleeding may suggest that a 
woman is at risk for iron-deficiency anemia[61] 
Table (6) summarizing the signs and symptoms of iron deficiency anemia :[62] 
Common symptoms Rare symptoms  
Fatigue  Pica  
Headache  Glossitis  
Exertional dyspnea Koilonychias (spoon nail) 
Difficulty concentrating  Dysphagia (difficulty swallowing ) 
 
1.11.3.7 Tests that used to Diagnose Iron Deficiency Anemia: 
 A complete blood count (CBC), to look at the shape, color, number, and size of your 
blood cells. 
 Iron tests, which measure the amount of iron in your blood.  
 A reticulocyte count, to see how well treatment is working. Reticulocytes are immature 
red blood cells produced by the bone marrow and released into the bloodstream. When 
reticulocyte counts increase, it usually means that iron replacement treatment is effective. 
 A ferritin level test, which reflects how much iron may be stored in the body.[63] 
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1.11.3.8 Treatment of Iron Deficiency Anemia : 
Medical care starts with establishing the diagnosis and reason for the iron deficiency. In 
most patients, the iron deficiency should be treated with oral iron therapy, and the 
underlying etiology should be corrected so the deficiency does not recur[64]If the anemia 
is caused by a disease or condition such as bleeding in the stomach, so one must take steps 
to treat the problem. If not having enough iron in the diet or not being able to absorb iron, 
one must develop a plan to increase iron level up take .[63] 
So Treatments may include dietary changes and supplements, medicines, and surgery. 
Severe iron-deficiency anemia may require a blood transfusion, iron injections, or 
intravenous (IV) iron therapy[63]. 
Most people will start to feel better within a few days of beginning the treatment. Even 
though they will need to keep taking the pills for several months to build up the iron stores. 
Sometimes it takes up to 6 months of treatment with iron supplements before iron levels 
return to normal.[63]. 
For the treatment of iron deficiency anemia, current guidelines recommend the dose of 60 
to 120mg of elemental iron of ferrous sulphate per day for a minimum duration of 3 
months in adolescents and adults.[65, 66] 
1.11.3.9 Types of iron salts that used in iron supplement: 
 
 There are two main iron salts forms (ferric and ferrous irons) and numerous formulation( 
amino-acid chelates, carbonyl iron, polysaccharide-iron complex, combination products, 
extended-release products, sulfate, gluconate , etc)  All dietary iron have to be reduced to 
the ferrous form to enter the mucosal cells; therefore ferrous iron is absorbed three times 
more readily than the ferric form[67] 
Several iron salts are available in tablet or liquid form for oral ingestion, as listed in Table 
(7)... Ferrous sulfate, which supplies 65 mg of elemental iron per 200 mg tablet, is the most 
widely used oral iron preparation.[68] 
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Table (7) available oral and parenteral iron preparations: [68] 
Intramuscular preparations Intravenous preparations Oral preparations 
Iron sorbitol citrate  Iron dextran(FeH2O4S) Ferrous sulfate  FeSO4 
 Iron dextrin Ferrous fumarate (C4H2FeO4) 
 Iron hydroxyl saccharate 
Ferrous gluconate(C12H22FeO14) 
 Iron sodium gluconate Ferrous succinate ( C4H4FeO4) 
  Iron polymaltose  
  Polysaccharide iron complex  
*this list is not exhaustive: other oral and parenteral iron preparations may be available.   
 
Most of these preparations vary in the bioavailability, efficacy, side-effects, and cost. The 
iron-containing preparations available on the market vary widely in dosage, salt, and 
chemical state of iron (ferrous or ferric form) contained in the preparation[65] as shown in 
table (8) 
 However, in clinical practice bivalent iron salts such as Ferrous Sulfate , ferrous 
gluconate, and ferrous fumarate are more widely used and are preferred over ferric iron 
preparations [69], 
The bivalent iron salts  preparations usually present good bioavailability (between 10 and 
15%), while bioavailability of iron ferric preparations is( 3 to 4 %)[70]. This is due to the 
extremely poor solubility of ferric iron in alkaline media and the fact that ferric iron needs 
to be transformed into ferrous iron before being absorbed into the enterocyte by the 
transporter DMT-1among ferrous preparations, Ferrous Sulfate, remains the established 
treatment of iron deficiency.  (Santiago 2012) 
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Table (8) differences between bivalent and trivalent oral iron preparation. (Santiago 2012) 
Comments Iron supplement 
 
More adverse effects if not in a prolonged-release 
formulation. 
Bivalent 
 Ferrous fumarate (Fe2+) 
ferrousgluconate (Fe 2+) 
 Ferrous sulphate (Fe2+) 
 Ferrous glycine sulphate(Fe2+)  
Poorer absorption. 
More expensive. 
A greater number of intake 
Trivalent 
 Iron protein  succinylate (Fe3+) 
Iron  polymaltose complex (Fe3+)  
 
The Side Effects of Iron Therapy: Is a common problem in the treatment of patients with 
iron deficiency. Gastrointestinal disturbances such as nausea, heartburn, pain, constipation, 
and diarrhea are the most commonly reported side effects, irrespective of the type of iron 
preparation. This occasional intolerance is usually viewed as a limiting factor for oral iron 
therapy, as it may impact patient compliance. The incidence of the gastrointestinal side 
effects seems to be generally associated with the use of unnecessary high doses of iron as 
reported [71, 72] . 
Incidence of gastrointestinal side effects has been shown to be lower with controlled-
release iron formulations compared to conventional ferrous salt preparations in three large 
controlled randomized studies[73-75] 
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Table (9) A Chart Summarizing the Iron Supplement Product Marketed in Palestine. 
 
Active ingredients Company Brand name 
Ferrous sulphate +Folic acid Jerusalem Jefrol –R ( tab) 
Ferrous gluconate+ Folic acid+BcomlexVit 
+Nicotinamide+Ca-Pantothenate 
Jerusalem Jefrol –V (tab) 
Iron(III)hydroxide polymaltose complex Jerusalem Ferriton -3 (syrup+drops) 
Iron(III)hydroxide polymaltose complex C T S 
company 
Ferriple -3 (syrup+drops ) 
Ferrous fumarate +folic acid Bier zaiet 
company 
Fergole (tab) 
Ferrous iron +folic acid Meditec Ferric pregnancy(tab) 
Iron Fumrate +Vit B12+ folic acid +Vit C Dana med Super Iron (tab) 
Ferrous Sulphate dried +folic acid Abbott Ferro grad folic (tab) 
Ferrus bisglycenate National 
company 
Ferro more (tab) 
Ferrous gluconate Jamieson IRON 35(tab) 
Iron sulphate +folic acid +Iodine +Zn +  Vit B6+Fish 
oil 
Catlant Ferro med plus (tab) 
Iron bisglycinate +Vit B12+ folic acid Hadas Ferro green (tab) 
1.12 Iron deficiency anemia in Palestine: 
According to the Palestinian Ministry of Health in its annual health report 2014 there is 
significant percent of pregnant and postnatal Palestinian women who attained to the 
ministry of health clinics in the west bank suffering mild and sever iron deficiency anemia 
according to this table (10)and postnatal table(11)  
 
  
 
 
35 
 
Table(10) Distribution of Anemia Percentage between Pregnant Beneficiaries in MCH 
Centers by Type and District, West Bank, Palestine, 2014[76] 
 
Total 
NumberMore11
gm/dl 
%of 
Anemia 
Number of 
Anemia 
% Mild 
Anemia 
11-
9gm./ 
dl 
 %
Moderate 
Anemia 
7-9gm./ 
dl 
 %Severe 
Anemia 
Less 
7gm/ dl 
25894 19869 25.6% 6625 24.7% 6386 0.9% 237 0.0% 2 
 
Table (11) Distribution of Anemia Percentage of Postnatal Beneficiaries of MCH Centers 
by Type and District, West Bank, Palestine, 2014[76] 
Total 
Number 
More11gm/dl 
%of 
Anemia 
Number of 
Anemia 
 %Mild 
Anemia 
11-
9gm./ 
dl 
 %
Moderate 
Anemia 
7-9gm./ 
dl 
 %Severe 
Anemia 
Less 
7gm/ dl 
39707 30714 22.6% 8993 21.1% 8395 1.4% 569 0.1% 29 
 
So as we conclude from the two table that  significant persent of pregnant and post 
partnatal women(which are amjor groub at risk  suffering  iron defcincy anemia ) , about 
26% of pregnant women attanding to MOH cliniecs are suffring mild anemai and about 
23% of post natal women attanding to the MOH cilinecs also suffers mild  anemai  
1.13 Back ground on ferrous gluconate: 
Chemical Names:Ferrous Gluconate; Iron(II) gluconate dihydrate; Iron(II) D-gluconate 
dihydrate; Ferrous gluconate [USP];[77] 
Molecular Formula:C12H26FeO16 
CAS NO                        299-29-6 
Formula weight             482.17 
Assay                            97-102%  Not less than 95% on the dried basis 
PH                                 7.0-8.5 (10% sol) 
 
 
36 
 
Description:           Fine yellowish-grey or pale greenish-yellow powder or granules 
having a slight odour resembling that of burnt sugar  
Functional uses :         Colour, stabilizer, nutrient supplement. 
[78] 
 
 
1.13.1  Chemical and Physical Properties:[77] 
Melting Point:188°C 
Boiling Point:673.6 oC at 760 mmHg 
Vapour:4.95E-21mmHg at 25°C 
Flash Point:673.6 oC at 760 mmHg 
Solubilities: Soluble with slight heating in water; practically insoluble in 
ethanol[78]Soluble in glycerin[79] 
Solubility  increase  by adding  Citric acidorCitrate Ions[80]1 gram dissolves in about 10 
ml of water with slight heating and in 1.3 ml of water at 100 deg C. It forms supersaturated 
solutions which are stable for a period of time[81] 
Color/Form:The color of /ferrous gluconate/ solution depends on pH; they are light 
yellow at pH 2, brown at pH 4.5, and green at pH 7. The iron rapidly oxidizes at higher 
pH.[81] 
Stability: 
Aqueous solutions are stabilized by the addition of glucose[82]. 
Approximetely  neutral solutions undergo rapid oxidationOxidation retarded and stability 
improved by buffering to pH of 3.5 to 4.5 with citrate buffer[80] 
Decomposition: When heated to decomposition it emits acrid smoke and irritating 
fumes[83] 
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Pharmacological Classification: 
Hematinics:  Agents which improve the quality of the blood, increasing the hemoglobin 
level and the number of erythrocytes. They are used in the treatment of anemia's [77] 
Absorption: 
Gastrointestinal absorption of iron is adequate and essentially equal from ferrous, sulfate, 
fumarate, gluconate, succinate, glutamate, and lactate.[84] iron bioavailability is about 
18%  
 
Methods of Manufacturing: 
Prepared from barium gluconate and iron sulfate[82] and also by metathesis between hot 
solution of calcium gluconate and ferrous sulfate... . It may also be produced by heating ... 
ferrous carbonate with proper quantity of gluconic acid in aqeous solution/Dihydrate.[80] 
Formulations/Preparations: 
Capsules 435 mg (equivalent to 50 mg of elemental iron); Elixir 300 mg (equivalent to 
37.5 mg of elemental iron)/5 mL; Tablets 320 mg (equivalent to 40 mg of elemental 
iron).[85] 
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2.1 Problem Statements: 
 
According to the World Health Organization(WHO), iron deficiency is the most common 
form of malnutrition in the world, affecting around 2 billion people worldwide, which 
corresponds to 25% of the population globally.[86]. 
According to annual Palestinian health report 2014(MOH) the percent of pregnant women 
attending to the ministry of health clinics in the west bank  suffering mild iron deficiency 
anemia is 24.7%  . and postnatal women attending ministry of health clinics in the west 
bank suffering mild iron deficiency anemia is 22.6%   [76]. 
 In the Palestinian market,  the iron supplements are available in different pharmaceutical 
dosage  forms such as  tablet, syrup, injection.atc these dosage forms are developed by 
using  different salts of iron (sulphate, fumerat, polysaccharides complex sugar, 
gluconateets.). , iron deficiency anemia is still the main malnutrition in the developing and 
developed country. This raises and important research question to investigate the reason of 
these phenomena.  
Oral iron preparations may cause nausea, vomiting, dyspepsia, constipation, diarrhea or 
dark stools. All these side effects are a result of excess release of ferrous from the tablet 
and the inability of receptor to uptake all released iron from the stomach and upper part of 
the intestine, hence  when ferrous iron  reach the high PH intestine the iron change from 
Fe
+2
 to Fe
+3
 which poorly absorbed by intestine causing  the side effect as stool 
discoloration and constipation and other side effects ,accordingly: Ineffectiveness of the 
present formulation of ferrous salts supplements (poor absorption equals poor 
bioavailability).and  the discontinuation of treatment because of major GI disturbance. Are 
two major causes for not eradicate iron deficiency anemia problem . 
To overcome this problem there are many techniques to use and formulate iron tablets with 
good iron absorption and bioavailability, i.e.   
1- A change to another iron salt may also be beneficial; ferrous gluconate and ferrous 
fumarate are less irritating than ferrous sulfate. 
Therapeutically there is no difference between ferrous sulfate and ferrous gluconate as both 
salts of irons are prescribed for the treatment of anima. There is slight difference between 
these two as ferrous sulfate is inorganic supplement and ferrous gluconate is organic 
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supplement. The rate of absorption of organic supplements is more in comparison to the 
inorganic supplements so large amount of ferrous sulfate is required to get desired effects. 
In addition  Some patients  better tolerate ferrous gluconate than ferrous sulfate[87], 
2- Controlling the gastric emptying time of the iron tablet from the stomach that is the 
absorption window for the iron. By increasing the duration of drug retention in the 
stomach, increase the chance of drug absorbance and its bioavailability through providing 
more contact time and absorption area [88] This property can be made by mean of  
Gastroretentive drug delivery system. 
 In this study we use effervescent floating drug delivery system. Where  carbon dioxide is 
released  when exposed to acidic stomach contents and trapped within the swollen hydro-
colloid polymer causing it to   float and consequently increasing gastric retention time [89]. 
3- formulate a sustained release iron tablet by using special Swelling agent/Gel forming 
polymer as Hydroxy propyl methyl cellulose (HPMC) that is frequantlly  used in the 
controlled release solid dosage formulations,  HPMC also forms a gelatinous layer upon 
hydration in gastric fluid[15]  that controls  the release of  iron from the tablet whish help 
in gradual release of the iron in a manner helping the synchronies to its absorption by   
divalent metal  receptors located in the wall of the stomach and upper part of the intestine, 
in this way the saturation of receptor and the loss of the excess iron in the stool are 
prevented . 
In our formulation we gathered all these techniques in one ferrous gluconate effervescent 
floating Gastroretentive sustained drug delivery system. 
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2.2Literature review:  
 
Seth and Tossounian were the first to propose a simple and effective hydrodynamically 
balanced system (HBS) in 1975 ,[90]they used a large quantities of HPMC and fatty 
materials to regulate flotation and drug release ,and have a bulk density lower than gastric 
fluid . The inventors claimed that these floating systems remain in buoyant state upon the 
stomach content for a prolonged period of time and they recommended in using these 
system when aiming to enhance the gastrointestinal transit time or to obtain a sustained 
local action in specific site of absorption in the stomach and intestine [91] 
This dosage form has been marketed by Hoffman La-Roche for sustained release form of 
Diazepam as (Valerlease) and for sustain release of combination of L-dopa and 
Benserazide (Modapar) .[92] 
As a result of these novel HBS systems many research field and various other floating drug 
delivery system and formulation was proposed for achieving the same result. Researchers 
specialized in formulation aspect e.g. Banker, et al,1975/Watanabe .et al,1976/ Seth & 
Tossounian,et al,1978,1979/Balton& Desai et al, 1986 and many others and Researchers 
specialized in the in vivo investigation on human volunteers e.g. Bechgaard&Ladeforged 
et al,1978/Seth &Tossounian et al ,1984/ Davis et al 1986/Timmermans et al 1989 and 
many other researchers [91]. 
All these studies and investigation helped to get a better idea about the GRDDS: 
1- The best drug candidate to be used in these systems. 
2- Types of GRDDS. 
3- Best physiological condition of the stomach for these system  
4- Dosage form characteristic. 
5- The bulk density of the tablet and floating duration time are the main parameter to 
describe the effectiveness of the GRDDS. 
From these findings, we can conclude that iron is a good candidate as floating drug 
delivery system  and knowing that the drug(iron) which is soluble in acidic media and 
absorbed in specific window of absorption in the stomach and upper part of the intestine 
which means it requires to increase gastric retention time allowing the maximum 
absorption of the drug(iron) and controlling the rate of the release . 
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Bothwell TH, Charlton RW, Cook J:(1979) in their book demonstrated various 
pharmaceutical preparations(sustained release formulation) that are designed to minimize 
the peak concentration of iron in the gastrointestinal lumen by slowing its dissolution rate . 
And Side-effects consequently  will  be reduced significantly , but this  may be  due to a 
reduction in the amount of absorbed iron. Indeed the efficacy of these preparations cannot 
be evaluated reliably unless absorption and side effects are examined together. The use of 
delayed-release preparations has been criticized because of its reduced extent of  
absorption and increased cost.[93] 
 
James at.al.(1990) had formulated an iron gastric delivery system (GDS) containing  
hydroxypropyl methylcellulose(HPMC), hydrogenated vegetable oil, crospovidone, 
microcrystalline cellulose, xanthan gum, talcum powder, magnesium stearate, and colloidal 
silicone dioxide(P. R. Sheth, J. Tossounian, US patent 4126 672) [94] to which ferrous 
sulphate is added .When  the  capsule containing the above  ingredients is placed in 
aqueous solution, the gelatin coating dissolves but the matrix remains intact. Buoyancy is 
made by the hydrocolloids which form a hydrated boundary layer that impedes the entry of 
water into the core of (GDS) it retained in the stomach for 5-12 h. 
They conducted a study on 9 volunteers given a  GDS containing  50 mg elementary iron 
once daily versus  other group was given ferrous sulphate elixir with 50 mg elementary 
iron 3 times a day .They found a three to four-fold higher absorption from GDS iron 
compared with ferrous sulphate elixir. 
In a double blinded study on 200 women (18-48 year) giving one group GDS tablet (50 mg 
elementary iron) once a day vs. placebo and a group given 3 time conventional iron 
sulphate (50 mg elementary iron ) vs. placebo to study the gastric side effect. It was found 
that the conventional preparation was associated with a significantly higher frequency of 
nausea and anorexia, whereas there were no significant differences in reported side-effects 
between subjects receiving GDS or placebo. A single GDS capsule daily provides the same 
amount of absorbed iron as conventional ferrous sulphate given three times daily, and does 
not produce gastrointestinal side-effects.[95] 
Simmon et.al:(1993) studied the efficacy of oral iron supplementation during pregnancy 
by using a gastric delivery system (GDS) 376 pregnant women (16-35year) suffering mild 
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anemia was selected in the study and divided into 3 groups the first group was given a 
placebo the second group was given 2 tablets of ferrous sulphate conventional tablet (100 
mg elementary iron) The third group was given 1 tablet of the GDS of ferrous 
sulphate(50mg elementary iron).There was a significant and comparable improvement in 
hematologic and iron-status measurements in the two groups of women given iron whereas 
iron deficiency evolved in women given no iron supplement. They conclude that by 
eliminating gastrointestinal side effects and reducing the administration frequency of an 
iron supplement to once daily, a GDS offers significant advantages for iron 
supplementation of pregnant women. [96]. 
BahriNajafi et al : (2012) formulated Effervescent gastro retentive tablets of ferrous sulfate 
plus ascorbic acid. Tablets containing HPMC K4M and  Carbopol as retarding polymers 
showed desirable in-vitro properties. The optimized formulation released the drug in a 
Higuchi-order fashion and demonstrated a short buoyancy lag time, total floating time of at 
least 18 h and could maintain drug release for 12 h. Based on pharmacokinetic parameters, 
once-daily administration of this new formulation can be a suitable alternative formulation 
compared to common forms of iron available in the market.[97]. 
Conviron ®: manufactured by Ranbaxy Laboratories Ltd/ INDIA is a Colloidal gel forming 
FDDS containing Ferrous Sulphate. And marketed in  two formulations : 
Conviron-TR ® contains :  
 Dried ferrous sulphate (TR) 60 mg 
Folic acid 1.5 mg, 
Ascorbic acid 75 mg, 
Pyridoxine hydrochloride 1.5 mg, 
Cyanocobalamin 15 mcg. 
 
Conviron –Fort®: contains the  same active pharmaceutical ingredients  as Conviron-
TR ® in addition  to Folic Acid 15 mg and  Zinc 15 mg. 
 This product is Prescribed For the treatment of anemia, but not recommended for pregnant 
or lactating women [98] 
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 As a Conclusion: few studies were conducted using the formulation of sustained or 
Gastroretentive dosage forms of iron. All studies used ferrous  sulphate  as the active 
ingredient . Moreover, all studies focused on decreasing its side effects formulating it as a 
sustained release tablets without  presenting a clear  enhancement in the absorption of iron    
2.3 Main Objective of the Study: 
 
The main objective for this study is to formulate an effervescent floating sustained release 
tablets containing 150 mg ferrous gluconate and 10 mg of ascorbic acid (vitamin C ) as 
absorption aid , the tablets were presumed to  remain  floating in the stomach for sufficient 
period of time to  facilitate better  absorption of  iron   in the stomach and upper part of the 
intestine .  
2.4 The Specific Objectives of the Study are: 
 
1-To formulate 150mg ferrous gluconateas floating gastro retentive delivery tablets which 
provide a sustained release of iron by choosing appropriate prototypes and amounts of 
polymers and by following either wet granulation or direct compression manufacturing 
methods.    
2- To study the floating behavior, floating lag time and floating time.  
3- To develop a suitable assay, suitable method of analysis for the ferrous gluconate tablet. 
4- To Conduct an in vitro release study for the tablet and study the kinetics of the release. 
6- To conduct quality control tests for the powder (pre formulation QT) and for the tablet 
(post formulation QT). 
7- To study the accelerating stability studies  of ferrous gluconate tablets for one and three 
month. 
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2.5 Advantage of Floating Gastric Retentive Drug System:[18] 
 
The hydrodynamic balanced system (HBS) also called Floating drug delivery system 
(FDDS) is an oral dosage form (capsule or tablet) designed to prolong the residence time 
of the dosage form within the GIT. It is a formulation of a drug with gel forming 
hydrocolloids meant to remain buoyant in the stomach contents. Drug dissolution and 
release from the dosage form retained in the stomach fluids occur at the pH of the stomach 
under fairly controlled conditions Floating systems are one of the important categories of 
drug delivery systems with gastric retentive behavior 
 Floating drug delivery systems have many advantages as listed below:: 
1) The principle of HBS can be used for any particular medicament or class of medicament 
2) The HBS formulations are not restricted to medications which are principally absorbed 
from the stomach. Since it has been found that these are equally efficacious with 
medications which are absorbed from the intestine e.g. Chlorpheniramine maleate. 
 3) The HBS are advantageous for drugs absorbed through the stomach e.g. ferrous salts 
and for drugs meant for local action in the stomach and treatment of peptic ulcer disease 
e.g. antacids. 
 4) The efficacy of the medications which administered using the sustained release 
principle of HBS has been found to be independent of the site of absorption of the 
particular medicaments 
5) Administration of a prolonged release floating dosage form tablet or capsule will result 
in dissolution of the drug in gastric fluid. After emptying of the stomach contents, the 
dissolved drug will be available for absorption in the small intestine. It is therefore 
expected that a drug will be fully absorbed from the floating dosage form if it remains in 
solution form even at alkaline pH of the intestine 
6) When there is vigorous intestinal movement and a short transit time as might occur in 
certain type of diarrhea, poor absorption is expected under such circumstances it may be 
advantageous to keep the drug in floating condition in stomach to get a relatively better 
response. 
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 7) Gastric retention will provide advantages such as the delivery of drugs with narrow 
absorption windows in the small intestinal region.  
 8) Many drugs categorized as once-a-day delivery have been demonstrated to have 
suboptimal absorption due to dependence on the transit time of the dosage form, making 
traditional extended release development challenging. Therefore, a system designed for 
longer gastric retention will extend the time within which drug absorption can occur in the 
small intestine medicaments which are absorbed from the intestine e.g. Chlorpheniramine 
maleate 
Methods for preparing floating dosage form; 
 The Following approaches can be used for preparing floating dosage form: 
1) Using gel forming hydrocolloids such as hydrophilic gums, gelatin, alginates, cellulose 
derivatives, etc. 
(2) Using low density enteric materials such as methacrylic polymer, cellulose acetate 
phthalate. 
 (3) By reducing particle size and filling it in a capsule. 
 (4) By forming carbon dioxide gas and subsequent entrapment of it in the gel network 
 (5) By preparing hollow micro-balloons of drug using acrylic polymer and filled in 
capsules. 
 (6) By incorporation of inflatable chamber which contained in a liquid e.g. solvent that 
gasifies at body temperature to cause the chambers to inflate in the stomach  . 
The factors which govern the effectiveness of active medicaments in HBS are  : 
1) Amounts of active ingredient to produce therapeutic effect. 
 2) Bulk density. 
 3) Hydrophilic and hydrophobic properties.  
4) Stability in gastric fluids. 
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Stages of floating mechanism as it shows in figure (16):(Shaha, Patel et al. 2009) 
(A) Penetration of water; 
 (B) Generation of CO2 and floating; 
 (C) Dissolution of drug.  As it shows in the Figure (16) 
Fig (16) stages of floating mechanism in FDDS 
 
 
2.6  Why ferrous gluconate used in our study? 
The standard preparation used in the oral management of iron deficiency anemia is ferrous 
sulfate. Other salts, such as ferrous gluconate and ferrous fumarate, are as effective as 
ferrous sulfate when administered in equivalent amounts of elemental iron[99]. 
 
 Calculation of dosage for iron preparations should always be based on the amount of 
elemental iron to be administered. Ferrous sulfate salt contains 20% of elemental iron, 
ferrous gluconate contains ~12% and ferrous fumarate contains 33%. ,[99] 
Oral iron preparations may cause nausea, vomiting, dyspepsia, constipation, diarrhea or 
dark stools, Pill-induced esophageal injury (Ferrous sulfate may injure the esophageal 
mucosa because it produces an acidic solution once it is dissolved (pH <3). These effects 
are generally dose-related and, with the exception of dark stools, usually subside with 
continued therapy.[99]. 
 To minimize the intolerance, 
Lower doses may be administered initially: not very effective..The medication may be 
given with or after meals. But this will reduce the bioavailability of iron absorption as the 
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PH will raise and reduce the formation of Fe 
+3
into Fe
+2
 that is the required form of iron to 
be absorbed by the transporter. A change to another iron salt may also be beneficial; 
ferrous gluconate and ferrous fumarate are less irritating than ferrous sulfate 
Therapeutically there is slight difference between ferrous sulfate and ferrous gluconate as 
both forms of irons are prescribed for the treatment of anima.  
The slight difference between these two is as ferrous sulfate is inorganic supplement and 
ferrous gluconate is organic supplement. 
The rate of absorption of organic supplements is more in comparison with inorganic 
supplements so large amount of ferrous sulfate is required to get desired effects.  Some 
patients can better tolerate ferrous gluconate than ferrous sulfate[87]. 
 
 
 
 
. 
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Materials and  Methods: 
3.1 Materials and Reagents: 
 
All materials used in the formulations of ferrous gluconate FDDS are of pharmacopeia 
grade , the materials and reagents used are the ferrous gluconate powder and the reagent 
1,10-O-phenanthroline were donated by      Jerusalem pharmaceuticals  Company. 
 HPMC K4M, HPMCK15M, HPMCK 100 M , sodium carbonate ,microcrystalline 
cellulose, starch, ethylcellulose , Mg stearate, Vit C (ascorbic acid ),  Polyvinylpyrrolidone  
K30, Iso Propyl Alcohol Stearic acid were donated from Bir Zeit  Medical Company . 
3.2 Tools and Equipment: 
Table (12) list of the tools and equipments   used in the study: 
 
Pharmaceuticals supplied by  Source/Model  Equipment/Apparatus  
Jerusalem Company Electrolab– India Dissolution apparatus 
Jerusalem Company Pharmachine– China Rotary tablet Press  
Jerusalem Company Pharmachine– China 
HMLHT-2 Tablet Hardness 
apparatus. 
Jerusalem Company Copley scientific – UK 
Copley fribilator Friability 
apparatus 
Alquds University 
Erweka AR402Heusenstamm 
lab 
Mixer machine 
Alquds University 
Heraeus Oven /Kendro lab 
product 
Tray Oven 
Jerusalem Company 
Parameter Generation & Control 
(PGC) –US 
Walk In Humidity Chamber 
Incubator 30/65 
Jerusalem Company Firlabo– France Firlabo Incubator 40/75 
Jerusalem Company  Metrohm  pH meter  
Jerusalem Company 
Merch Hitadi U290, UV.visible 
spectrophotometer  
UV-Visible spectro- photometer  
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3.3 Spectrophotometric Determination of Iron: 
 
The Ferroin Reaction which involves the formation of a red complex of ferrous iron with 
certain heterocyclic nitrogen compounds has been extensively used for the colorimetric 
determination of small quantities of iron.[100]  
Iron in its ferrous state  reacts with the complexing agent 1,10- Phenanthroline as  shown 
below: 
 
Ferrous ions (Fe
2+
) can readily be air-oxidized to the ferric state , Fe
3+
 . To determine the 
total iron in the sample ,a mild reducing agent is added before the color is developed . 
Hydroxyl amine hydrochloride salt is used for this purpose .[101]  
The possibly oxidized  Fe
3+ 
 ions are reduced to ferrous ions according to the reaction. 
2Fe 
3+
 +2NH2OH.HCl + 2 OH 
-
 ↔ 2 Fe
2+
  +N2+ 4 H2O + H
+
 + Cl 
-
 
A red–orange complex ion is formed which is an indication that ferrous 1-10-
phenanthroline complex is formed which is then measured by the UV visible 
Spectrophotometer at 510 wave length. 
Taking benefits from this complexing reaction we conducted a Drug Release Study for 
ferrous gluconate. For this purpose a standard calibration curve was created.  
To create the calibration  curve stock solution of 0.1 N was prepared by dissolving ferrous 
gluconate  in 25 ml 0.1 N sulfuric acid then  dilute with distilled water a series of solutions 
with different concentrations   were made as illustrated in table (13) . 
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Table (13) standard solutions preparation for calibration curve  
 
Final volumes (ml) Volume taken from the stock solution Test-tube # 
Up to 10 ml .05 ml 1 
Up to 10 ml 0.1 ml 2 
Up to 10 ml 0.5 ml 3 
Up to 10 ml 1.0 ml 4 
Up to 10 ml 2.0 ml 5 
 
Then take 5 ml from each test tube in table (13) add to it 5 ml from 1,10-phenanthroline  
and 1 ml hydroxyl amine (HA) and dilute it with distilled water up to 25 ml in a volumetric 
flask then measure the absorbance by the UV-Spectrophotometer at 510 nm  . 
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3.4 Preparation of effervescent floating tablets: 
Wet granulation and direct compression were used to prepare the tablets. 
3.4.1 Wet Granulation Method: 
 
The compositions of the tablets are listed in table (14).All powders except Mg stearate 
were mixed in(Ereweka mixer) at 100 rpm for 5 minutes. All the powder were passed 
through sieve no. 40, then the mix was put in a mortar and the wetting agent that was 
prepared earlier was added gradually to the mix .The granules were prepared manually by 
adding a solution of calculated quantity of PVP K30 in sufficient solvent (Isopropyl 
Alcohol (10 % PVP K30)). The wet mass is then passed through a mesh#20. Then  dried 
by using  oven (Heraeus Oven) for 30mins at 50 C° .the dried granules were passed 
through sieve with mesh # 20 ,then mix for 5 min finally the lubrication Mg stearate was 
add and mixed for 3 minutes   then the mixed granules were compressed by a( Rotary 
tablet press ) by Scored Circular Falt- 12 mm diameter punch  ..  
The compressed tablets were kept  in airtight container for further study. 
The amount of the ingredients in these various formulations was selected on the basis of 
formulation by trial . Gradual increase or decrease was conducted on one ingredient at a 
time to obtain the best results in floating behavior. 
 
 
  
 
 
54 
 
Table (14) summary of formula used in  wet granulation method 
Formula B.N(quantities in mg/tablet ) 
 
Component  
 
Function 
F1 F2 F3 F4 F5 F6 
Fe gluconate Active ingredient 150 150 150 150 150 150 
HPMC100 
Swelling agent 
Gel forming agent  
264 240 ***** **** **** ***** 
HPMCK4 
Swelling agent 
Gel forming agent  
**** ***** ***** 240 240 240 
HPMC K15 
Swelling agent 
Gel forming agent 
***** ***** 240 ***** **** **** 
Citric acid  Acidulent 10 10 10 10 10 10 
Na HCO3 Gas forming agent  40 40 40 40 50 34 
Ethyl 
cellulose  
Floating enhancer ***** 24 24 24 14 30 
PVPK30 Binder   10 10 10 10 10 10 
Vit C  
Anti-oxidant and 
absorption enhancer  
14 14 14 14 14 14 
Mg.stearate Lubricant  5 5 5 5 5 5 
tablet weight   483mg 483mg 483mg 483mg 483mg 483mg  
the total weight of the tablets doesn't include the Mg stearate weight  
3.4.2 Direct  Compression Method: 
 
The ingredient that were used are shown in table (15) , The tablets were prepared by first 
passing the powder through mesh #40 then mixing  all except Mg stearate in( Ereweka 
mixer) for 5 min at 100 rpm then add the Mg stearate (lubricant) was added and mix for  5 
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min . The  powder blend  was compressed by using a (Rotary tablet press))by Scored 
Circular Falt- 12 mm diameter bunch, .All compressed  tablets were kept  in airtight 
container for further study. 
Table (15) summary of formulas used in direct compression method 
 
Component  
 
Function 
Formula B.N (quantities in mg/tablets) 
H1 H2 H3 H4 H5 H6  H7 
Fe gluconate Active ingredient 150 150 150 150 150 150 150 
HPMC100 
Swelling agent 
Gel forming 
polymer **** **** **** 240 240 240 240 
HPMCK4 
Swelling agent 
Gel forming 
polymer **** 240 ***** **** **** ***** **** 
HPMC K15 
Swelling agent 
Gel forming 
polymer ***** ***** 240 ***** **** **** ***** 
Citric acid Acidulent 10 10 10 **** **** ***** 10 
Na HCO3 
Gas forming 
agent 40 40 40 40 40 50 40 
Ethyl 
cellulose Floating enhancer 244 24 24 24 34 24 24 
Vit C 
Anti-oxidant and 
absorption 
enhancer  14 14 14 14 14 14 14 
Mg.stearate Lubricant 5 5 5 5 5 5 5 
Starch disintegrator **** **** **** 10 **** ***** **** 
MCC Disintegrator 20 **** **** **** **** **** **** 
tablet weight  483mg 483mg 483mg 483mg 483mg 483mg 483 
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3.5 Quality Control Tests of   tablets: 
 
In vitro evaluation of floating tablets was performed to assess the physicochemical 
properties and release characteristics of the developed formulations 
3.5.1 Pre-compression parameter: 
 
a) Angle of Repose:[102]  
 
The angle of repose of a powder bed is the maximum angle that allows a heap of powder to 
remain stable without failing. It is measured by putting 20 gm. of the powder as a single 
heap on a flat surface (a glass surface 30 cmX 30 cm), then raising the surface to the point 
at which the powder heap starts to fall apart (powder starts to flow). At this point the angle 
made between the flat surface and ground surface is measured as the angle of repose 
Table (16) the relationship between Angle of repose and powder flow is as follows in 
 
Powder flow Angle of repose 
Excellent < 25 
Good 25-30 
Passable 30-40 
Very poor >40 
 
b) Compressibility Index: [103]  
The compressibility index has become the simple and fast method of predicting powder 
flow characteristics . 
The compressibility index is determined by measuring both bulk volume (unsettled 
apparant volume V° ) and the tapped volume (the final tapped volume  Vf). 
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Compressibility index = V°- Vf/ V° *100% 
Table (17) Scale of flowability 
Compressibility Index (%) Flow charcters 
≤ 10 Excellent 
11-15 Good 
16-20 Fair 
21-25 Passible 
26-31 Poor 
32-37 Very poor 
>38 Very very poor  
 
3.5.2 Post-compression parameters: 
3.5.2.1 Shape of Tablets: Compressed tablets were visually examined fortheir shapes. [104]. 
3.5.2.2  Tablet Dimensions:Thickness and diameter:  measured using a calibrated varniear 
caliper.Tablets of each formulation is picked randomly and thickness  measured 
individually[104] 
3.5.2.3Hardness :[30]: Hardness indicates the ability of a tablet to withstand mechanical 
shocks while handling it was measued by using HMLHT-2 Tablet hardness tester. 
3.5.2.4 Friability test:[104] The friability of tablets  was expressed in percentage (%). The 
tablets were  initially weighed (W initial) and transferred into a friabilator(Copley 
friabilator  tester). The friabilator was operated at 25rpm for 4 minutes or run up to 100 
revolutions.  6,5 weight of tablet should be measured first and placed  in the apparatus then 
the tablets were reweighed again (Wfinal). 
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The % friability was then calculated by : 
%F = (w1-w2)/w1*100% 
The acceptance  % Friability value of tablets is not more than (1%) original weight.   
3.5.2.5 Weight Variation Test :[104] : Ten tablets should be selected randomly from the 
batch and weighed individually to check for weight variation.  Variation  allowed is 
indicated  by U.S. Pharmacopoeia.. 
Table (18) the USP acceptable limits for the weight variation 
 
3.5.2.6Buoyancy/ Floating Test:[15] The time between introduction of dosage form and its 
buoyancy in  the1.2 N HCl puffer  and the time during which the dosage form remain 
buoyant were measured. The time taken for dosage form to emerge on surface of medium 
called Floating Lag Time (FLT) or Buoyancy Lag Time (BLT) and total duration of time 
by which dosage form remain buoyant is called Total Floating Time (TFT). 
3.5.2.7 Swelling Study:[15] The swelling behavior of a dosage form was measured by 
studying its weight gain or water uptake. Tablets were intended in the dissolution apparatus  
900 ml of 1.2 HCl at 37 C
0
,and at different time points ( ,5 , 1,2.3,5,7 hour) 3 tablets were 
removed from the three dissolution basckets  then lightly dried by a pieace of tissue paper 
to drain the loose  water  and weighted . 
The swelling index is  given by the equation: 
WU = (W1 – W0)/ W0 x 100 % 
Wt = Weight of dosage form at time t 
W0 = Initial weight of dosage form 
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3.5.2.8In vitro drug release for the formulation : the tablets that passed the floating test were 
tested for drug release [105, 106]  The invitro drug release was studied by conducting 
dissolution test for tablets. Dissolution was carried out using USP XIII dissolution 
apparatus type II (paddle type). 900  milliliters of 1.2 N HCl, which was maintained at 
37°C, was used as the dissolution medium. The speed of paddle was maintained at 50 rpm  
for 10 hours .Five milliliters samples were withdrawn at the time intervals periodically up 
to 10 h and replaced with equal volume of fresh dissolution medium maintained at the 
same temperature. The samples were filtered and suitably dilutedthen assayed for iron 
content.Allexperementswere carried out in triplicates.  
3.5.2.9Drug content uniformity study:  6 tablet were randomly chosen and each tablet was 
weighted and put in mortar and pestle and crushed   
1) A standard solution was prepared  by dissolving 150mg of Fe Gluconate in 50 ml 0.1 N 
Sulphuric Acid then dilute  to 200 ml by Distilled Water . A 10 ml of the standard solution 
was withdrawn then  dilute with Distilled  Water to volume 100 ml   . withdraw 3 ml from 
it +5 ml complexing agent+ 1 ml HA   and measure the absorbance at UV 510 wave length 
2)   and measure at the absorbance ƛ 510 nm   wavelength . 
3) Sample preparation: transfer 1 tablet(grind it first ) into 200 ml volumetric 
flask.Dissolve by adding 50 ml 0.1 N sulphuric acid (may use magnetic stirrer to help in 
dissolving it)dilute with Distilled  Water to volume then take 10 ml from the sample and 
dilute up 100 ml distilled water .then withdraw 3 ml from it +5 ml complexing agent + 1ml 
HA and measure the absorbance at UV 510 wave length, this  was in triplicate . 
3.5.3  Stability test for tablet : [107] 
Stability testing is a routine procedure performed on drug substances and products and is 
employed at various stages of the product developmentThese studies are required to be 
conducted in a planned way following the guidelines issued by ICH, WHO and-or other 
agencies. Importance of various methods followed for stability testing of pharmaceutical 
products, andgeneral recommendations on the storage conditions have been given by ICH 
and WHO. [108]. 
The packing container  which was used HDPE 60 ml jars, with2*1 g silica gel caps+ 
sealing and 30 tabs for Jar  
Two storage conditions were applied  for the stabilitye test . 
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1) the intermediate storage condition=30±2°C/65±5% RH  (WHO) usingWalk In Humidity 
Incubator[108] 
2) accelarated storage test = 40±2°C/75±5% RH (WHO)using Firlabo Incubator (Cha, 
Gilmor et al. 2001) 
After the specified storage  peroids which are  1 month and three months the following 
tablets performance tests were carried out :  
1- Invitro dissolution drug release  test. 
2- Content uniformity  (assay ). 
3- Harrdness. 
3.6 Kinetics of drug release: 
To investigate the mechanism of drug release from the  selected formulation, the drug 
release results  were   evaluated  by  all models for kinetic studies through appalling  in DD 
Solver program  
3.7 Mathematical modeling of dissolution rate profile: 
In vitro dissolution has been recognized as an important element in drug development. 
Under certain conditions it can be used as a surrogate for the assessment of Bio- 
equivalence. Several theories /kinetics models describe drug dissolution from immediate 
and modified release dosage forms. 
 There are several models to represent the drug dissolution profiles where ƒt is a function of 
t(time) related to the amount of drug dissolved from the pharmaceutical dosage system. 
The quantitative interpretation of the values obtained in the dissolution assay is facilitated 
by the usage of a generic equation that mathematically translates the dissolution curve in 
function of some parameters related with the pharmaceutical dosage forms[109]. 
Mathematical models have been used extensively for the parametric representation of drug 
release kinetics from GRDDS formulations. Models that have been used include, the zero 
order, first order, Higuchi, Korsmeyer-Peppas and Weibull models. [109] 
The major objectives of mathematical modeling are as listed below:  
1.  Designing the new drug delivery system based on general release expression.  
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2.  Prediction of the exact behavior of drug or drug release rates from and drug diffusion 
behavior through polymers, thus avoid excessive experimentation.  
3.  Optimization of the release kinetics.  
4. Elucidation of the physical mechanism of drug transport by simply comparing the 
release data to mathematical models. 
3.7.1 Zero order models 
Drug dissolution from pharmaceutical dosage forms that do not disaggregate and release 
the drug slowly (assuming that area does not change and no equilibrium conditions are 
obtained) can be represented by the following equation:[109] 
Qt = Q0 + K0 t  
Where Qt is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the 
solution and K is the zero order release constant.  
3.7.2 First order model  
 The pharmaceutical dosage forms containing water-soluble drugs in porous matrices 
follow first order release kinetics, and can be expressed by the equation: 
Qt = Q0     
Where Qt is the amount of drug released in time t, Q0 is the initial amount of the drug in 
the solution and k is the 1st order release constant. The above equation in decimal 
logarithm will take the form, 
ln Qt = ln Q0 + kt  
This equation implies that a graphic of the decimal logarithm of the amount of drug versus 
time will be linear. The dosage forms that follow this dissolution profile release the drug in 
a way that is proportional to the amount remaining in the interior of the dosage form, in 
such a way that the amount of drug released by unit of time diminishes. Thus any system 
obeying this model releases the drug in such a way that the remaining amount in the 
system governs the rate of release of drugs [109] 
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3.7.3 Higuchi Model   
In 1961 Higuchi introduced the most famous and often used mathematical equation to 
describe the release rate of drugs from matrix system initially; it was valid only for planar 
systems. It was later modified and extended to consider different Geometries and matrix 
characteristics including porous structure. Higuchi developed an equation for the release of 
a drug from an ointment base and later applied it to diffusion of solid drugs dispersed in 
homogeneous and granular matrix dosage system. In this model, it is assumed that solid 
drug dissolves from the surface layer of the device first; when this layer becomes 
exhausted of drug, the next layer begins to be depleted by dissolution through the matrix to 
the external solution. In this way the interface between the regions containing dissolved 
drug and that containing dispersed drug moves into the interior as a front [109].  
In a general way it is possible to resume the Higuchi model to the following expression 
(generally known as the simplified Higuchi model): 
Qt = KHt
0.5 
Where, KH is the Higuchi dissolution constant. Higuchi describes drug release as a 
diffusion process based on the Fick’s law, square root time dependent. This relation can be 
used to describe the drug dissolution from several types of modified release pharmaceutical 
dosage forms, as in the case of some transdermal systems and matrix tablets with water 
soluble drugs. This modified Higuchi relationship has been used to describe drug release 
from various types of modified release pharmaceutical dosage forms  [109]. 
3.7.4  Korsmeyer- Peppas Model: 
Korsmeyer developed a simple semi empirical model, relating exponentially the drug 
release to the elapsed time (t). 
Qt/Qα = Kkt 
n
 
Where Kk is a constant incorporating structural and geometric characteristic of the drug 
dosage form and n is the release exponent, indicative of the drug release mechanism as 
shown in Table(16). 
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Table( 19): Various drug transport mechanisms 
Drug transport mechanism Release exponent (n) 
Fickian diffusion 0.5 
Anomalous transport 
Non fickian diffusion  
0.5<n<1.0 
Case-II transport 1.0 
Super Case-II transport Higher than 1.0 
 
The Release exponent can be obtained from the slope and the Constant (Kk) obtained from 
the intercept of the graphical relation between logarithmic versions of left side of the 
equation versus log t.[12] 
3.7.5 Hixsonñ Crowell model: 
 
Hixson and Crowell (1931) recognized that the particlesí regular area is proportional to the 
cube root of its volume. They derived the equation 
W0
1/3
 -  Wt 
1/3
  = κ t 
where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt is the 
remaining amount of drug in the pharmaceutical dosage form at time t and κ (kappa) is a 
constant incorporating the surfaceñvolume relation. The equation describes the release 
from systems where there is a change in surface area and diameter of particles or 
tablets[110] 
3.7.6 Selection of Best Model: 
 
The selection of the appropriate model in the drug release studies is critical to ensure the 
effectiveness of the study.  There are various criteria for the selection of the mathematical 
models which are based on the statistical treatments. The most widely used method 
employs the coefficient of determination, R
2
, to assess the fit of the model equation. This 
method can be used when the parameters of the model equations are similar. But when the 
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parameters of the comparing equations increased; a modification is incorporated in this 
technique where an adjusted coefficient of determination (R
2
 adjusted) given by:   
 
Where n is the number of dissolution data points and p is the number of parameters in the 
model. Hence, the best model is the one with the highest adjusted coefficient of 
determination. A value for R
2
 adjusted > 0.950 is considered acceptable for the purposes of 
comparison of modeling dissolution profiles generated. 
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 Result and Discussion: 
 
4.1 Spectrophotometric determination of iron : 
From the calibration curve we got a linear relationship ( R
2
 = 0.991) which means a highly 
precision and accuracy. 
table (13)Absorbance of ferrous phenanthroline complex versus concentrations of 
ferrous gluconate at ƛ 510 nm 
Test tube # Concentration (mg/ml) absorbance 
A 0.001 0.028 
B 0.002 0.06 
C 0.01 0.292 
D 0.02 0.444 
E 0.04 0.844 
Fig (17) Calibration curve of ferrous gluconate 
 
 
 
 
 
y = 20.55x + 0.0336 
R² = 0.9913 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0 0.01 0.02 0.03 0.04 0.05
ab
so
rb
an
ce
  
 
 
concentration 
 
 
67 
 
The aim of this study was to creat a gastroretentive floating system of ferrous gluconate , 
that release iron in a sustained release manner. 
Ferrous salts  are  good candidates to be formulated as floating system as its absorption 
window is in the stomach and the upper part of the intestine . but  iron absorption  as 
GRFDD faces two proplems:i.e. 
1- It is a heavy metal with a high molecular weight . 
2 –It is  highly soluble in water. 
 The tablets should allow enough water to water entrance so as to form CO2 to initiate 
floating but at the same time allowing slow release of the iron . . 
So we must formulate a floating system that help us in maintain the integrty of the tablet 
by slowing down the disentigration of the tablet.The challenge was to choose the 
appropiate polymer compisition to achive these aims . 
The requierments was to formulate a floating system that has a short floating lag time( not 
more than 2 minutes) to make sure that our tablets will rapidlly float  as they enter the 
stomach to escape gastric emptying in the case a house keeper wave and to obtian a 
floating time for minimum 12 hours  to facilitate  iron release for prolonge period time in 
sustained manner to allow a once dailly use of the tablet. 
During  our study we prepared  13 diffrenet  formulas with different excipient as shown in 
tables (14,15) .Seven formulas were prepared by the so called  Direct Compression method 
and the other  six by wet granulation . 
The tablets prepared for  each formula were tested interms of buoyancy lag floating time 
(LFT) and total floating time (TFT) ,the acceptence criteria for buoyancy tests are included 
in table (20)   
The results of the FLT and TFT of all formulations are shown in table (20). Our work was 
based on formulating a formulations by trail  method to get best floating results befor 
persuing to dissolution testing .  
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Table (20 ) the floating lage time (FLT) and the total floating time (TFT) for all fromulas we 
studied in both wet garanulation and direct compression methods. 
Formula of 
wet 
garnulation 
FLT TFT Formula of 
direct 
compression 
FLT TFT 
F1 Fail  to float Fail H1 Fail to float Fail 
F2 Took > 5min Up to 12 h H2 12 sec Disentegrated 
within 1 h 
F3 Took >2 min Dissapeared 
after 10 min 
H3 Rapid 
disentegration 
Disentegrated 
F4 58 sec Dissapeared 
after 15 min 
H4 8 sec Disentegrate within 
1 h 
F5 disentegrated disentegrated H5 4:45 min Up to 12 h 
F6 Fail to float  Fail  H6 15 sec Disentegrate 
within30 min 
 H7 40sec (avarage 
FLT for 6 tablets 
Up to 24 h 
*FLT:floating lag time 
*TFT: toltal floating time . 
*min: minute  
*sec: seconde *h: hour 
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4.2  preparation of effervescent floating tablets :  
4.2.1 Wet granulation method's formulas :  
 
Formula F1 :  it didn’t float  with little formation of gas bubbles . 
Here we will discuss the results of each fromula and the logic of the changes done . 
By studying the excpients uesd in this formula , HPMCK 100,000 polymer was used wich 
has  a high viscous polymer to help in entrapping water and the generated gas to form 
floating and also slow down iron release HPMC100,00 is  used here as a gel forming 
agent,and in contact with water it helps in entrapping  the produced carbon dioxide  to 
create a bulk desity for the tablet lesser than the density of gastric content so the tablet will 
float .This is the same with HPMCk15, HPMCk 4.which varry in the molucular weight and 
viscocity charastristics .[15] 
citric acid:is used as acidulant, because this floating gastro retentive system should be 
taken after meals which will raise the PH of the stomach that will affect the gas formation, 
to solve this problem we added  the citric acid to make sure that the inner part of the tablet 
is acidic to help in  rapide formation of gas and rapid floating behavior .[15]. 
NaHCO3:Is an  Effervescent compound .( Sodium bicarbonate,  with citric acid ). When 
these compounds come in contact with the acidic gastric contents, carbon dioxide is 
liberated and gets entrapped in swelled hydrocolloids, which provide buoyancy to the 
dosage forms .[15]as it shows in the follwing reaction :  
NaHCO3 + HCl → CO2 +H2O 
PolyVinylPyrrolidone, K 30 (Povidone):povidone solutions are used as binders in wet-
granulation processes [111]. 
Vitamine C: used here as Antioxidant.[112] 
Mg stearate : used as hydrophobic lubricant, 
 Tablet from formula 1  failed to float .This can be explained by .in contact with water the 
tablet matrix is thought to form a very viscous gel layer, that prohibits the  entrance  of 
water into the tablet core subsequently  and slow down the gas formation processes.So  the 
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total density of the tablet  remains higher  than the gastric contents density so fail to float( 
it was heavy to float) . 
Formula F2:.it needed to float with in >5 min and stayed floating up to 12 hours . 
Addition of  Ethyl Cellulose  to  formula  F1.improved the floating behavior ,hence   ethyl 
cellulose has bulk density less than one,  thus   it is  used for enhancing the buoyancy of 
the formulation. [113].the compination  of   Ethyl cellulose and  HPMCK100,000  
enhanced the floating time  .The tablet floated with in 5 minutes  and stayed floating for 12 
hours, which is considered good but not with  in the acceptance criteria that we determined 
in this study.The effect of Ethyl cellulose is thought to be due to weakening of the viscous 
gel that HPMC K100,000 makes, so helping in the formation of gas by decreasing the total 
density of the tablets .The combination of ethyl cellulose and a hydrophilic component 
such as HPMC offers a flexible system to control the drug release by changing the 
viscosity, substitution type and concentration of HPMC [114] 
Formula F3: This formula F3 took more than 2 minutes to floate and 10 minutes to 
disintegrate. 
It is seen that using K15 instead of K 100,000 reduced the floating lag time becouse  of 
reduced visicosity of the K15 polymer . But with  time, more water enters the tablet , more 
gas will form and entraped by the gel .But this HPMCK15  dose not  have the desired 
polymer entanglement to hold this pressure, and coused  a rapid distintegration  of the 
tablet after (10 min).It formed an efferviscent tablet that did not provide a sustained release 
.This formula had a lag time of more than 2 min which also not complying with the 
floating requirments (less than 2 min). So we tried a polymer having less vescosity in the 
following formulation. 
Formula F4: it took 58 seconds to float and 15 minute to disentgrate . 
In this formula F4 we used a  lower viscosity  HPMC polymer which is HPMC K 4 to 
study if this will decrease the floating lag time of the tablet .  
As we observed, the tablet took only 58 seconds to float wich is very good. This because 
the low viscosity grade polymer allows  rapid entrance of the water to the tablet so rapid 
gel forming layer of the polymer and rapid gas fromation and entrapment in the gel layer 
causing the the tablet to float,.But with time as more water enters and more gas forming the 
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low viscosity polymer couldn’t handle the pressure from the gas that is formed causing the 
tablet to disentegrate arapidlly with in 15 minutes So, in the following formulation we tried 
to change the ratio of ethyl cellulose and NaHCO3 to see if this will improve the floating 
characteristics. 
 Formula F5: Failed to float and rapid disintegrated  . 
 Increasing the percentage of sodium bicarbonate with decreasing the percentage of ethyl 
cellulose resulted  a tablet that rapidly disintegrated and failed to float  
 . 
Formula F6 : alsofailed to float,and very little of gas bubbles  was noticed . 
The increase of the ethyl cellulose which is a more hydrophopic polymer.Lead to a 
decrease inthe entrance of water and low formation  of  the required amount of gas to be 
entraped and help floating  of the tablet . 
Formula F2 proved to have  the closest properties to our requirments  . The main  proplem 
in this formula was the long floating lag time , that  may be due to  the use of  the PVP K30 
as binding agent  . 
. 
4.2.2 Direct  Compression  Method: 
 
 The results for the tablet floating are  sumarrized in table (22) .  
Formula H1: failed to float. 
In order to check our conclusions from the previous studies ,we tried the same polymers in 
Direct compression method.  
In this  formula   ethylcellulose was used without gel forming polymer .Ethyl cellulose 
prevented the entrance of water into the tablet core, and supsequently no gas was evolved ,   
as a result no gas genration occurred and the tablet did not float.. 
In  this formulation ,we introduced the Microcrystaline cellulose as a hydrophillic polymer 
to counteract the hydrophobicity of the ethylcellulose . as a result no gas genration 
occurred and the tablet did not float . 
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Formula H2: it has good floating time ,12 secondes, but a rapid disintegration of the 
tablet was observed within 1 houre . 
This may be due to the introduction of  HPMCK 4 .in the formulation satisfactory intiation 
of floating was obtained , but the tablet disintegrated in 1 hour .This is probably due to the 
fact that the polymer dosent have the required integrity and entanglement to hold the 
trapped gas . 
Formula H3 : failed to float, and  was a rapidly disintgrated  . 
It is abvious that even  HPMC K 15 (intermediate viscosity polymer), dosent have the 
required integriety and entanglement to hold the trapped gas and attain the required total 
floating time . 
Formula H4 : In this formula there was also a rapid floating within 8 seconds but 
disintegration within 1 hour .  
Here we added HPMC100,000 as gel forming polymer , and according to the previous 
result in using this polymer in wet granulation method we add starch .In attempt to increase 
the entrance of water initially to decrease floating lag time .The result was that  the tablet  
floated  rapidly (within 8 seconds) . However effervesces effect was so strong and a rapid 
disintegration occurred. So we thought to retard the water entrance by increasing the 
amount of the ethyl cellulose. 
Formula H5:In this formula there was a delay in the floating up to 4:45 minutes, 
succeeded in floating for 12 hours.  
Here we removed the starch, increased the ethyl cellulose amount to study the effect of 
increasing the ethyl cellulose amount on the floating behavior of the tablet. We observed 
that a delay in the floating lag time took place (more than 4 minute).This formula stayed 
floating for 12 hours. At this step we concluded that a fine tuning of the amount of ethyl 
cellulose and NaHCO3 must be done. 
Formula H6:in this formula there was a rapid disintegration within 30 minutes and 
rapid floating lag time 15 sec . 
Here to overcome the long lag floating time of the tablet in H5, by decreasing the ethyl 
cellulose amount and increasing the amount of NaHCO3 .This increase the gas forming 
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agent caused a rapid and large amount of gas formation causing rapid floating and rapid 
disintegration of the tablet. 
At this point, we concluded that there should be a factor that increases the formation of gas 
but keeps that tablet integrity. 
So we decided to keep the amounts in formula H4 but introduce the citric acid. 
Formula H7: .In this formula there was a rapid floating lag time 40 seconds and total 
floating time up to 24 hour. 
Here the amount of the ethyl cellulose and NaHCO3 remain unchanged but we added the 
citric acid as enhancer for gas formation with the NaHCO3. 
This approach is appeared to be the right combination. Citric acid used helped in internal 
gas formation, and ethyl cellulose helped in preventing the tablet from disintegration.  
The result was a good effervescent gastro retentive floating tablet that had a short floating 
lag time and long floating time and maintained its integrity. This complies with our 
objectives. So formula was a successful formula and the one to conduct all the quality 
control  and stability tests  
So formula(H7) was chosen to conduct quality control test that is required. 
4.3  The pre-compression physical properties for the powder for H7: 
 The powder blend was evaluated for flow properties. The angle of repose value was 20 
o
 
degrees (table (16)) the flowability of powder blend is excellent. 
Compressibility index = V° - Vf / V° *100% 
The compressibility index of the powder was =100%*(22,5-19.12)/22.5= 15  
This means the powder blend has good flow properties ( table 17 ) 
4.4 The post- compression physical properties for the tablets (for formula 
H7): 
4.4.1 Shape of Tablets:it is a flat faced bisect tablet 
4.4.2 Dimensions of the tablets:the tablets have 12 mm radius and 4.4 mm thickness. 
4.4.3  Friability test : by using the equation of friability : 
%F = 100*(W1-W2)/W1 
% F= 100*(6.5g-6.435g)/6.5g = 1  
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A maximume mean wight loss from the tablets of not more than1% is cosidered accepteple 
for most of the productus . 
4.4.4 Hardness of the tablet (H7):  
 Sample of 6 tablets was taken from  formulation (H7): the tablets  average weight 
was:478.5 mg,and the hardness results are shown in table (20) as shown in table (20)  
Hardness(kgf) 6.3 
 
7.3 
8.8 
7.2 
5.5 
8.1 
Average 7.2 
 
These results agree with USP requirements. Oral tablets have a hardness of 4 to10 kg 
[115]; it means that our tablets are in the acceptable range. 
4.4.5 Weight variation: randomly sample was taken from formulation (H7)and their weight 
were measured . the results are shown in table (21) 
Table (21) Results of  Weight Variation Quality Control Test 
 
Weight variation for 10 tablets  
Table number Tablet weight ( g) %weight deviation 
from average 
#1 0.483 0.104 
#2 0.483 0.104 
#3 0.483 0.104 
#4 0.485 0.518 
#5 0.480 0.518 
#6 0.481 0.311 
#7 0.482 0.104 
#8 0.485 0.518 
#9 0.484 0.311 
#10 0.479 0.725 
average tablets weight (g)  0.4825  
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All tablets weight are within acceptance limit, none of the tablets deviated from the 
allowed limit according to the USP limits (if tablet weight >324 mg the allowed limit is ± 
5%) 
4.4.6 Content Uniformity Test: 
Table (22) shows  the results of the content uniformity for 6 tablets 
 Content Uniformity 
 
Tablet No. Abs () 
% 
Content  
1 0.4999 95.09226 
2 0.5252 99.90489 
3 0.4981 94.74986 
4 0.5093 96.88035 
5 0.5003 95.16835 
6 0.4983 94.7879 
abs of STD 0.5272 
 Average   96.09727 
 
To ensure the consistency of dosage units, each unit in abatch should have a drug 
substance content within narrow range around the label claim.So according to the USP 
criteria the compressed tablets coated or non coated for 6 dosage form unites should be 85-
115% of lable claim (USP 2011). So as shown in table (22) the result are within the 
accepetd range  
 
4.4.7 Buoyancy / Floating Test: here we studied the floating lag time (FLT), and Toltal 
floating time (TFT). for all the formula in both method the direct compression and the 
conventional wet garanulation .as the result is summrized in table (23)-  
 For the LFT test we bicked 6 tablets from the batch (H7) with avarage wighet 0.4825 g .in 
1.2 PH buffer in dissolution  
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Table (23) Floating time measured for 6 tablet 
Average Tablets Weight Tablet number  Floating Time(Sec) 
478.5 mg 1 52 
 2 50 
3 45 
4 20 
5 55 
6 20 
Average FLT for( H7)  40.333 
 
So H7 shows that it has a very good byouncy behvioer as its avarage FLT is 40 sec which 
is very good and it keep byount for at least 24 hours which all result helped us in choosing 
this formula H7 for further study . 
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4.4.8 Swelling Study:the swelling properties of formula( H 7) were determaine , and table (24) summrises the results . 
The table (24) showes the results for the swelling index for formula H7 
 
 
weight of tablets (gm) 
 
% water uptake for each tablet 
 
time (h) basket1 basket2 basket3 
%water uptake 
tab1 
%water uptake 
tab2 
%water uptake 
tab3 
Average swelling 
index 
standard deviation for the 
swilling  
0.5 0.7137 0.6835 0.7003 47.76 41.51 44.98 44.75 3.13 
1 0.7849 0.791 0.8044 62.50 63.76 66.54 64.27 2.06 
2 1.005 0.952 0.9603 108.07 97.10 98.81 101.33 5.90 
3 1.1011 1.0656 1.111 127.97 120.62 130.02 126.20 4.94 
5 1.303 1.172 1.140 169.77 142.65 136.02 149.48 17.88 
7 1.186 1.15 1.310 145.54 138.09 171.221 151.62 17.37 
14 0.8887 0.9141 1.30 83.99 89.25  87.98 86.62 3.71 
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Fig (18) Swelling Index with time: 
 
 
It is shown in table (24) and graph (17) that in the initial 5 hours there was an increase in the weight due to swelling of the polymer. After the 5th 
hour the weight was stable then it decreased after wards indicating that erosion of the polymer beginning to tack place   
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4.4.9 The in vitro release study for Ferrous gluconate :(H7) 
The results of the dissolution pattern of ferrous gluconate for the formula H7 is shown in table (25) and fig (18)  
The study was done on 6 tablets for 10 hours. 
Table (25) shows the result of the % release of the ferrous from the tablet of formula H7 for 10 hours 
 
Time 20 min 
%Release 
30min 
%Release 
1hr 
%Release 
2hr 
%Release 
3hr 
%Release 
4hr 
%Release Tablet# Absorbance Absorbance Absorbance Absorbance Absorbance Absorbance 
1 0.0484 10.88 0.0669 15.04 0.0869 19.53 0.1367 30.73 0.1677 37.70 0.2083 46.83 
2 0.0508 11.42 0.0751 16.88 0.0957 21.51 0.1384 31.11 0.1718 38.62 0.2115 47.54 
3 0.0569 12.79 0.063 14.16 0.0995 22.36 0.1475 33.16 0.1938 43.57 0.2292 51.52 
4 0.0506 11.37 0.0669 15.04 0.0912 20.50 0.1355 30.46 0.1703 38.28 0.2359 53.03 
5 0.0705 15.84 0.0632 14.20 0.1083 24.34 0.1524 34.26 0.1916 43.07 0.2112 47.48 
6 0.0528 11.87 0.0616 13.84 0.0944 21.22 0.1416 31.83 0.1841 41.38 0.2328 52.33 
   
 
 
 
 
 
 
 
 
 
 
%Average Release  12.36 14.86 21.58 31.92 40.44 49.79 
SD 1.824 1.103 1.658 1.497 2.571 2.798 
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Continue:  the result of the % release of the ferrous from the tablet of formula H7 for 10 hours  
5hr 
%Release  
6hr 
%Release 
7hr 
%Release 
8hr 
%Release 
9hr 
%Release 
10hr 
%Release Absorbance  Absorbance Absorbance Absorbance Absorbance Absorbance 
0.2405 54.06 0.2669 60.00 0.3041 68.36 0.3316 74.55 0.3545 79.69 0.3705 82.70 
0.2582 58.04 0.2662 59.84 0.3004 67.53 0.3656 82.19 0.3482 78.28 0.3594 80.22 
0.2583 58.07 0.287 64.52 0.3202 71.98 0.3504 78.77 0.3769 84.73 0.3862 86.20 
0.2536 57.01 0.278 62.50 0.314 70.59 0.3433 77.18 0.367 82.50 0.382 85.26 
0.27 60.70 0.3068 68.97 0.3458 77.74 0.3713 83.47 0.3937 88.51 0.4028 89.91 
0.272 61.15 0.3052 68.61 0.3455 77.67 0.3728 83.81 0.3984 89.56 0.4127 92.12 
            %Average 
Releases 58.17 
 
64.07 
 
72.31 
 
79.99 
 
83.88 
 
86.07 
SD 2.587 
 
4.043 
 
4.465 
 
3.757 
 
4.587 
 
4.417 
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Fig (19) Dissolution Release Profile of Ferrous Gluconate for Formula (H7). 
 
 
 A gradual sustained release of ferrous gluconate obtained with staisfactory properties 
between the 6 tablets tested . Up to this point we succedded in obtaining the required 
tablets features that exhibited both floating charactristics and sustained release of iron on a 
period of time more than 10 hours .This indicated possible use of this dosage form  once 
daily.  
4.4.10 In vitro release kinetics data analysis for optimized formula H7 : 
In the in vitro release data of the formulation (H 7) was examined with varoius release 
equation and kinetic models .The most familiar kinetics modle in sustained release tablets 
are shown in table (25). 
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Table (26 ) Mathematical Models used to describe Drug Release Kinetics from various 
Matrices[116] 
Systems that follow the Model Kinetic Model 
Water soluble drugs in porous matrix First Order 
Osmotic systems, transdermal systems 
drug release independent of drug 
concentration) 
Zero Order 
Diffusion matrix formulations Higuchi’s square root of time equation 
Erodible matrix formulations Weibull 
Erodible matrix formulations Hixon-crowell’s cube-root equation 
Swellable polymeric devices Korsmeyers-Peppa’s power law equation 
 
Our release data was intermeded to the DD Solver programe to fit the different kintecs 
release modle. The resulting R
2
 and the fitting curves are shown in table (27) ang fig (19) 
respectivlly . 
The R 
2
  are shown in table(27) for the 5 kintecs modle we studied : 
Model  R
2
 
Zero order R
2
 0.9057  
First order R
2
 0.9861  
Higuchi's  R
2
 0.9832  
Korsmeyer's R
2
 0.9974  n value: 0.616 
Hixon 's  R
2
 0.9815  
 
According to these results of R
2
 values we conclud that the korsmeyer pappas model is the 
best model that describes the release in our formula  hightest .This modelexplain the drug 
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relaesr from a swallable polymer device which is the exactform that we have.In this model, 
the value of n characterizes the release mechanism of drugs as it showes in this table (28). 
Table(28): The interperation of diffusion exponent (n) value for release from polymeric 
film 
Rate as a function of time Drug transport mechanism Release exponent n 
t
-0.5 Fickian diffusion 0.5 
t 
n-1 Non -Fickian transport 0.5<n<1  
Zero order release Case II transport n =1 
t 
n-1 Super case II transport >1  
 
So as it showes in the table( 28) that from the n value that our releasr follow the non-
fickian (anamolous) diffusion which acombination of both diffusion and erosion 
controlling the release of the drug.This result is also reflected  by the result of the swelling 
index that up to 7 houres, there is an increase in the swelling index of the tablet then after 
that there is a decrease in the swilling index wich indicates that there is an erosion process 
taking place in a later step after the beginnig of the diffusion  
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As it is seen in Figure (20) the best model in which the predicted curve fits the data is 
koresmeyerpeppas model.  
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4.4.11 Stability studies : 
4.4.11.1 For One Month:  
 
1- Disolution study for30 C/65 %RH:  for one month :   
Table (29) % release of iron from (6) tablets after one month stability at 30 C/65 %RH 
 
Time 
Absorbance 
1hr 
%release 
1 hr 
Absorbance 
5hr 
%release 
5 hr 
Absorbance 
10hr 
%release 
10 hr 
Tablet 1 0.0858 19.42 0.2388 54.05 0.3874 87.68 
Tablet2 0.0986 22.31 0.2679 60.63 0.422 95.51 
Tablet3 0.0877 19.85 0.2659 60.18 0.406 91.89 
Tablet4 0.0833 18.85 0.2498 56.54 0.4266 96.55 
Tablet5 0.0983 22.24 0.25 56.58 0.4102 92.84 
Tablet6 0.0875 19.80 0.267 60.43 0.42 95.06 
average 
 
20.41 
 
58.07 
 
93.26 
 
Disolution test for 40 C/75 %RH for one month :  
      
 
Table(30) % release of Fe from (6) tablet after one month stability at 40 
C/75 %RH 
 
Time 1hr 
%release 
1 h 
Absorbance 
5hr 
 
%release 
5 hr 
Absorbance 
10hr 
%release 
10 hr 
1 0.0927 20.98 0.2428 54.95 0.375 84.88 
2 0.1008 22.81 0.272 61.56 0.432 97.78 
3 0.089 20.14 0.2769 62.67 0.4266 96.55 
4 0.097 21.95 0.2788 63.10 0.389 88.04 
5 0.0892 20.19 0.271 61.33 0.451 102.08 
6 0.0977 22.11 0.278 62.92 0.431 97.55 
average 
 
21.36 
 
61.09 
 
94.48 
 
In compression to the result we got befor  dissolution test we founde no diferrence which 
give us a good idea that our tablets are stable after 1 month . 
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2. Assay : 
Table (31) showes the result of assay for(10) tablets after one month stability test at both 
30C/65 RH and 40C/ 75RH 
Assay : 
30/65 100.70% 
40/75 100.10% 
 
A  100 % consrvation of the ferrouse gluconate in the tablets after one month in both 
stability conditions was obtained. 
3- Hardness :  
Table (32) the hardness results for (6) tablets after one month at 30C/65 RH 
 
Incubator 
30/65 
Hardness 7.1 
  7 
 7.1 
8.4 
7.2 
6.5 
Average 7.2Kgf 
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Tablel (33) the Hardness results for (6) tablets after one month stability test at 40 C/75 RH 
 
 
Hardness of the formulation (H7)  as it shown in table (32,33) was presrved under the 
specified storage conditions up to 1 month . the hardness acceptence criteria for Oral 
tablets  in range of 4 to10 kg [115];  
 
 
4.4.11.2 Stability studies for three months : 
1- Disolution study for30 C/65 %RH:  for three months :  
30 C/65 %RH 
Table(34) shows the %release of iron from (6) tablets up to 10 hours after 3 month 
stability test at30 C/65 %RH. 
Time 
Absorbance 
1hr 
%release 
1hr 
Absorbance 
5hr 
%release 
5 hr 
Absorbance 
10hr 
%release 
10 hr 
1 0.0857 19.84 0.2426 56.17 0.3874 87.68 
2 0.0779 18.03 0.2415 55.91 0.421 95.29 
3 0.092 21.30 0.2414 55.89 0.406 91.89 
4 0.0826 19.12 0.229 53.02 0.411 93.02 
5 0.0832 19.26 0.23 53.25 0.403 91.21 
6 0.081 18.75 0.2355 54.52 0.3718 84.15 
average 
 
19.38 
 
54.79 
 
90.54 
 
Incubator40/75 Hardness 5.8 
 8 
 8.4 
8.1 
7.3 
9.2 
Average 7.8Kgf 
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Disolution study for 40C/75  RH for three monthes : 
40 C/75 %RH 
Table (35) shows the % release of iron from (6) tablets up to 10 hours after 3 month 
stability test at 40 C/75 %RH. 
 
Time 
Absorbance 
1hr 
%release 
1 hr 
Absorbance 
5hr 
%release 
5 hr 
Absorbance 
10hr 
%release 
10 hr 
1 0.0838 19.40 0.2405 55.68 0.3633 82.23 
2 0.086 19.91 0.2311 53.50 0.422 95.51 
3 0.0867 20.07 0.2447 56.65 0.401 90.76 
4 0.0897 20.7 0.245 56.72 0.408 92.34 
5 0.0855 19.79 0.242 56.03 0.4311 97.57 
6 0.0855 19.79 0.2301 53.27 0.432 97.70 
average 
 
19.95 
 
55.31 
 
92.70 
 
Fig (21) Release after different incubation conditions 
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In compression to the result we got befor in the dissolution test we founde no siginficant  
diferrence which give us a good idea that our tablets are stable after 3 month also. 
2- Assay : 
Table (36): the assay result of (6) tablets after three month at different incubation condition 
Conditions   Assay  
30/65RH 100.00% 
40/75RH 97.90% 
 
 It is Shown the stability of the tablet was preserved for 3 months under the specific 
conditions .Ferrus gluconat  still in the accpentance USP criteria that compressed tablets 
coated and uncoated for 6 dosage unites must be within 85-115% of lable claime . 
3- Hardness Tast:  
at 30 C/ 65 RH:  
Table( 37) hardness result of (6) tablets after 3 months at 30C/ 65 RH. 
Hardness 7.5 
 
  
9.2 
 7.9 
 9.5 
 9.5 
 8.4 
 Average 8.6 Kgf 
At 40C/ 75RH:  
Table ( 38) hardness result of (6) tablets after 3 months after 40C/ 75 RH. 
Hardness 8.9 
  
8.1 
8.2 
7.5 
7.7 
7.4 
Average 7.9 
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Hardness of the formulation (H7)  as it is shown in table (37,38) was presrved under the 
specified storage conditions up to 3 months The hardness acceptence criteria for Oral 
tablets  in range of 4 to10 kg [115]; 
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Part 5  
5.1Conclusion: 
 
This study showed the formulation of a gastroretentive floating tablet of ferrous glucont. A 
successful formulation was obtained using HPMC k100,000 and ethyl cellulose and 
specific amount of NaHCO3and citric acid .Direct compression method was more suitable 
in producing the required results of floating and sustained releasee. HPMC K4 and 
HPMCK15 was not sutabile to attain good floating characteristics.The obtained tablet (H7) 
showed a sustained release pattern that fitted the Korsmeyer Peppa's model, indicating a 
diffusion and erosion kintetics. The stability studies indicates that the tablets are stable up 
to 3 months when challanged with accelarated stability tests. This formulated 
gastroretentive tablet will hopefully increase the absorption of iron through providing 
sustained amounts at the absorption site; the duodenum. This will also decrease the side 
effects (as constipation) by decreasing the residual unabsorbed amount of  iron in the GIT 
.Future recomndations further in vivo sudies on human voulnteers is recommended 
.   
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5.2 .Appendix: 
 
5.2.1Hypromellose: (HPMC K 100.000/HPMCK 4/ HPMC K15): 
 
Chemical Name and CAS Registry Number: Cellulose hydroxypropyl methyl ether 
[9004-65-3] . 
EmpiricalFormulaandMolecularWeight:  
ThePhEur6.3describeshypromelloseasapartlyO-methylatedand O-(2-hydroxypropylated) 
cellulose. It is available in several grades that vary in viscosity and extent of substitution. 
Grades may be distinguished by appending a number indicative of the apparent viscosity, 
inmPas, of a 2% w/w aqueous solution at 208C. Hypromellose defined in the USP 32 
specifies the substitution type by appending a four-digit number to the nonproprietary 
name: e.g. hypromellose 1828. The first two digits refer to the approximate percentage 
content of the methoxy group (OCH3). The second two digits refer to the approximate 
percentage content of the hydroxypropoxy group (OCH2CH(OH)CH3), calculated on a 
dried basis.Itcontainsmethoxyandhydroxypropoxygroupsconforming to the limits for the 
various types of hypromellose;. Molecular weight is approximately 10000–1500000. 
Structural Formula: 
 
Functional Category : 
Bioadhesive material; coating agent; controlled-release agent; dispersing agent; dissolution 
enhancer; emulsifying agent; emulsion stabilizer; extended-release agent; film-forming 
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agent; foaming agent; granulation aid; modified-release agent; mucoadhesive; release-
modifying agent; solubilizing agent; stabilizing agent; suspending agent; sustained-release 
agent; tablet binder; thickening agent; viscosity-increasing agent. 
Applications in Pharmaceutical Formulation or Technology: 
 Hypromellose is widely used in oral, ophthalmic, nasal, and topical pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in film-
coating, and as a matrix for use in extendedrelease tablet formulations. Concentrations 
between 2% and 5% w/w may be used as a binder in either wet- or dry-granulation 
processes.High-viscosity grades may beused to retard the release of drugs from a matrix at 
levels of 10–80% w/w in tablets and capsules. Hypromellose is also used in liquid oral 
dosage forms as a suspending and/or thickening agent at concentrations ranging from 
0.25–5.0%. Depending upon the viscosity grade, concentrations of 2–20% w/w are used 
for film-forming solutions to film-coat tablets. Lowerviscosity grades are used in aqueous 
film-coating solutions, whileH326 Hypromellose higher-viscosity grades are used with 
organic solvents. Examples of film-coating materials that are commercially available 
include AnyCoat C, Spectracel, Pharmacoat, and the Methocel E Premium LV series. 
Hypromellose is also used as a suspending and thickening agent in topical formulations. 
Compared with methylcellulose, hypromellose produces aqueous solutions of greater 
clarity, with fewer undissolved fibers present, and is therefore preferred in formulations for 
ophthalmic use. Hypromellose at concentrations between 0.45–1.0% w/w may be added as 
a thickening agent to vehicles for eye drops and artificialt ear solutions.It is also used 
commercially in liquid nasal formulations at a concentration of 0.1%. Hypromellose is 
used as an emulsifier, suspending agent, and stabilizing agent in topical gels and ointments. 
As a protective colloid, it can prevent droplets and particles from coalescing or 
agglomerating, thus inhibiting the formation of sediments. Inaddition ,hypromellose is 
used in the manufacture of capsules, as an adhesive in plastic bandages, and as a wetting 
agent for hard contact lenses.It is also widely used in cosmetics and food products. 
Description Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder.[117] 
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5.2.2 Ethyl Cellulose: 
Chemical Name and CAS Registry Number: Cellulose ethyl ether [9004-57-3] 
Empirical Formula and Molecular Weight : 
Ethylcellulose is partially ethoxylated. Ethylcellulose with complete ethoxyl substitution 
(DS = 3) is C12H23O6(C12H22O5)nC12H23O5 where n can vary to provide a wide 
variety of molecular weights. Ethylcellulose, an ethyl ether of cellulose, is a long-chain 
polymer of b-anhydroglucose units joined together by acetal linkages. 
Structural Formula: 
 
Functional Category: Coating agent; flavoring agent; tablet binder; tablet filler; 
viscosityincreasing agent.E262 Ethylcellulose 
Applications in Pharmaceutical Formulation or Technology : 
Ethylcellulose is widely used in oral and topical pharmaceutical formulations; The main 
use of ethylcellulose in oral formulations is as a hydrophobic coating agent for tablets and 
granules. Ethylcellulose coatings are used to modify the release of a drug, to mask 
anunpleasant taste,or toimprovethestabilityofa formulation; for example, where granules 
are coated with ethylcellulose to inhibit oxidation. Modified-release tablet formulations 
may also be produced using ethylcellulose as a matrix former. Ethylcellulose, dissolved in 
an organic solvent or solvent mixture, can be used on its own to produce water-insoluble 
films. Higher-viscosity ethylcellulose grades tend to produce stronger and more durable 
films. Ethylcellulose films may be modified to alter their solubility, by the addition of 
hypromellose or a plasticizer; see Section 18. An aqueous polymer dispersion (or latex) of 
ethylcellulose such as Aquacoat ECD (FMC Biopolymer) or Surelease (Colorcon) may 
also be used to produce ethylcellulose films without the need for organic solvents. Drug 
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release through ethylcellulose-coated dosage forms can be controlled by diffusion through 
the film coating. This can be a slow 
processunlessalargesurfacearea(e.g.pelletsorgranulescompared with tablets) is utilized. In 
those instances, aqueous ethylcellulose dispersions are generally used to coat granules or 
pellets. Ethylcellulose-coated beads and granules have also demonstrated the ability to 
absorb pressure and hence protect the coating from fracture during compression. High-
viscosity grades of ethylcellulose are used in drug microencapsulation. Release of a drug 
from an ethylcellulose microcapsule is a function of the microcapsule wall thickness and 
surface area. In tablet formulations, ethylcellulose may additionally be employed as a 
binder, the ethylcellulose being blended dry or wetgranulated with a solvent such as 
ethanol (95%). Ethylcellulose produces hard tablets with low friability, although they may 
demonstrate poor dissolution. Ethylcellulose has also been used as an agent for delivering 
therapeutic agents from oral (e.g. dental) appliances. In topical formulations, ethylcellulose 
is used as a thickening agent in creams, lotions, or gels, provided an appropriate solvent is 
used.Ethylcellulose has been studied as a stabilizer for emulsions. Ethylcellulose is 
additionally used in cosmetics and food products. 
Description;  Ethylcellulose is a tasteless, free-flowing, white to light tan-colored 
powder.[117] 
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5.2.3  Citric acid :[117] 
Chemical Name and CAS Registry Number:2-Hydroxy-1,2,3-propanetricarboxylic acid 
monohydrate [594929-1} 
Empirical Formula and Molecular Weight:  C6H8O7H2O             210.14 
Structural Formula: 
 
Functional Category: Acidifying agent; antioxidant; buffering agent; chelating agent; 
flavor enhancer; preservative. 
Applications in Pharmaceutical Formulation or Technology: 
Citric acid (as either the monohydrate or anhydrous material) is widely used in 
pharmaceutical formulations and food products, primarily to adjust the pH of solutions. It 
has also been used experimentally to adjust the pH of tablet matrices in enteric-coated 
formulations for colon-specific drug delivery. Citric acid monohydrate is used in the 
preparation of effervescent granules, while anhydrous citric acid is widely used in the 
preparation of effervescent tablets. Citric acid has also been shown to improve the stability 
of spray-dried insulin powder in inhalation formulations. In food products, citric acid is 
used as a flavor enhancer for its tart, acidic taste. Citric acid monohydrate is used as a 
sequestering agent and antioxidant synergist; It is also a component of anticoagulant citrate 
solutions. Therapeutically, preparations containing citric acid have been used to dissolve 
renal calculi 
Description: 
 Citric acid monohydrate occurs as colorless or translucent crystals, or as a white 
crystalline, efflorescent powder .It is odorless and has a strong acidic taste. The crystal 
structure is orthorhombic [117]. 
 
 
111 
 
  
 
 
111 
 
 
5.2.4  Sodium bi carbonate:[117] 
Chemical Name and CAS Registry Number: 
Carbonic acid monosodium salt [144-55-8]. 
Empirical Formula and Molecular Weight:  NaHCO3            84.01 
Functional Category : Alkalizing agent; therapeutic agent. 
Applications in Pharmaceutical Formulation or Technology: Sodium bicarbonate is 
generally used in pharmaceutical formulations as a source of carbon dioxide in 
effervescent tablets and granules. It is also widely used to produce or maintain an alkaline 
pH in a preparation. In effervescent tablets and granules, sodium bicarbonate is usually 
formulated with citric and/or tartaric acid; combinations of citric and tartaric acid are of 
tenpreferredin formulations as citric acid alone produces a sticky mixture that is difficult to 
granulate, while if tartaric acid is used alone, granules lose firmness. When the tablets or 
granules come into contact with water, a chemical reaction occurs, carbon dioxide is 
evolved, and the productdisintegrates. Melt granulation in a fluidized bed dryer has been 
suggested as a one-step method for the manufacture of effervescent granules composed of 
anhydrous citric acid and sodium bicarbonate, for subsequent compression into tablets. 
Tablets may also be prepared with sodium bicarbonate alone since the acid of gastric fluid 
is sufficient to cause effervescence and disintegration. Sodium bicarbonate is also used in 
tablet formulations to buffer drug molecules that are weak acids, thereby increasing the 
rate of tablet dissolution and reducing gastric irritation. The effects of tablet binders, such 
as polyethylene glycols, microcrystalline cellulose, silicified microcrystalline cellulose, 
pregelatinized starch, and povidone, on the physical and mechanical properties of sodium 
bicarbonate tablets have also been investigated.Additionally, sodium bicarbonate is used in 
solutions as a buffering agent for erythromycin, lidocaine, local anesthetic solutions, and 
total parenteral nutrition (TPN) solutions. In some parenteral formulations, e.g. niacin, 
sodium bicarbonate is used to produce a sodium salt of the active ingredient that has 
enhanced solubility. Sodium bicarbonate has also been used as a freeze-drying stabilizer 
and in toothpastes. Recently, sodium bicarbonate has been used as a gas-forming agent in 
alginate raft systems and in floating, controlled release oral dosage forms for a range of 
drugs. Tablet formulations containing sodium bicarbonate have been shown to increase the 
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absorption of paracetamol, and improve the stability of levothyroxine. Sodium bicarbonate 
has also been included in formulations of vaginal bio adhesive tablet and in carbon dioxide 
releasing suppositories. Therapeutically, sodium bicarbonate may be used as an antacid, 
and as a source of the bicarbonate anion in the treatment of metabolic acidosis. Sodium 
bicarbonate may also be used as a component of oral rehydration salts and as a source of 
bicarbonate in dialysis fluids; it has also been suggested as a meansofpreventing 
radiocontrast-induced nephrotoxicity. Sodium bicarbonate is used in food products as an 
alkali or as a leavening agent, e.g. baking soda.  
Description :  Sodium bicarbonate occurs as an odorless, white, crystalline powder with a 
saline, slightly alkaline taste. The crystal structure is monoclinic prisms. Grades with 
different particle sizes, from a fine powder to free-flowing uniform granules, are 
commercially available 
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5.2.5  starch:[117] 
Functional Category: as Binding agent; compression aid; disintegrant; tablet and capsule 
diluent; tablet and capsule filler. 
Applications in Pharmaceutical Formulation or Technology : starch can be used in both 
capsules and tablets to improve flow ability, enhance disintegration and improve hardness. 
Description: Corn occurs as a white free-flowing powder. It is a compressed mixture .. 
Starch: Included in the FDA Inactive Ingredients Database (buccal tablets, oral capsules, 
powders, suspensions and tablets; topical preparations; and vaginal tablets). Included in no 
parenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-
medicinal Ingredients.  
 
5.2.6 Mg stearate :[117] 
Chemical Name and CAS Registry Number:Octadecanoic acid magnesium salt [557-04-
0} 
Empirical Formula and Molecular Weight:  C36H70MgO4             591.24 
The USP32–NF27 describes magnesium stearate as a compound of magnesium with a 
mixture of solid organic acids that consists chiefly of variable proportions of magnesium 
stearate and magnesium palmitate (C32H62MgO4). The PhEur 6.5 describes magnesium 
stearate as a mixture of solid organic acids consisting mainly of variable proportions of 
magnesium stearate and magnesium palmitate obtained from sources of vegetable or 
animal origin. 
Structural Formula:     [CH3(CH2)16COO]2Mg 
Functional Category:   Tablet and capsule lubricant. 
Applications in Pharmaceutical Formulation or Technology: 
 Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. 
It is primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25% and 5.0% w/w. It is also used in barrier creams.. 
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Description : Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. The powderisgreasytothe touch and readily adheres to the skin.  
 
5.2.7  Povidine : (PVP K30 ):[117] 
Chemical Name and CAS Registry Number: 
 1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8} 
Empirical Formula and Molecular Weight:  (C6H9NO)n   2500–3000000 
TheUSP32describes Povidine as a synthetic polymer consisting essentially of linear 1-
vinyl-2-pyrrolidinone groups, the differing degree of polymerization of which results in 
polymers of various molecular weights. It is characterized by its viscosity in aqueous 
solution 
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Structural Formula:  
 
Functional Category: Disintegrant; dissolution enhancer; suspending agent; tablet binder. 
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5.2.8  Microcrystalline cellulose:[117] 
Chemical Name and CAS Registry Number: Cellulose    [9004-34-6]. 
Structural Formula: 
 
Empirical Formula and Molecular Weight :(C6H10O5)n 36000 where n 220. 
Functional Category:  Adsorbent; suspending agent; tablet and capsule diluent; tablet 
disintegrant. 
Applications in Pharmaceutical Formulation or Technology: 
 Microcrystalline cellulose is widely used in pharmaceuticals, primarily as abinder/diluent 
in oral tablet and capsule formulations where it is used in both wet-granulation and direct-
compression processes. In addition to its use as a binder/diluent, microcrystalline cellulose 
also has some lubricant and disintegrant properties that make it useful in tableting. 
5.2.9 Ascorbic Acid : [117] 
Chemical Name and CAS Registry Number:  L-(þ)-Ascorbic acid [50-81-7]. 
Empirical Formula and Molecular Weight : C6H8O6        176.13 
Functional Category:  Antioxidant; therapeutic agent. 
Structural Formula:  
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5.2.10 ferrous gluconate : 
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تطوير وتقييم مخبري لمستحضر صيدلاني جديد يحتوي عمى ِفيّرس جموكونيت في حبه طافية في 
 المعدة لفترة زمنية طويمة
 عثمان عبد الرحيم حج حمد  عداد : هلاإ
 إشراف: د. طارق الجعبة
 الممخص:
 أكثريعتبر الناتج عن فقر الحديد  )مرض فقر الدم( الأنيميافان  الصحة العالميةمنظمو  إلىبالرجوع 
التي تحتوي عمى الحديد حاليا  الصيدلانية الأشكال إنانتشارا حول العالم  التغذيةسوء  أشكالشكل من 
 الأولالحديد لو امتصاص عالي في الجزء  إنامتصاص جيد لمحديد بسبب  إلىبالصيدليات لا تؤدي 
وبالتالي ومن اجل  مؤكسد. اكبر ىو الجزء غير الن الشكل الذي يمتص بصوره ا  و  الدقيقة الأمعاءمن 
 ،من الحديد ليا امتصاص عالي أشكالنحصل عمى امتصاص اكبر من الحديد يجب استخدام  إن
 الجانبية الأعراضعمى  أيضاوذلك لمتغمب  ، الأمعاءويجب توجيو امتصاص الحديد لمجزء العموي من 
 الناشئ عن سوء الامتصاص. الإمساكلمحديد مثل 
 
الذي يظل و  ))etanoculG suorreFتشكيل شكل دوائي من الحديد دراسةالكان اليدف من ىذه 
,ىذا الشكل الدوائي لو صفو  انو  طويمة لفترةو يقوم بتحرير الحديد  ،طويمة لفترة المعدةفي متماسكا 
بكميات  الأمعاء إمدادو بالتالي يتم  طويمةبعد فتره  إلا الأمعاء إلىولا ينزل  المعدةيطفو عمى السطح 
 ليتم امتصاصو تدريجيا.من الحديد  اليةمتت
 
 :من المبممرات متنوعةوالتي احتوت عمى كميات  ، الحبوب من  تجريبية من تركيبو أكثرقمنا بعمل 
 .الحبة كي تطفولات والتي تنتج الغاز اللازم صوديوم بيكربون وماده  CMPH,esolullec lyhtE
ىي التي  بالترطيبضغط المباشر و ليس التحبيب ال بوساطةالحبات التي صنعت  أن  النتيجةكانت 
 التي تطفو فييا و كميو الحديد التي تحررىا. الفترةمن حيث  المطموبةكانت ليا الصفات 
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مع كميات محدده من الصوديوم  000,001 KCMPHتركيبو كانت التي تحتوي عمى  أفضل
وكان تحرر الحديد  ساعة 24د عن لمده تزي طافية الحبةحيث بقيت  ،,esolullec lyhtEبيكربونات و
 لما ىو موجود في دساتير الادويو. مطابقةكانت  الحبةساعات و كل صفات  10منيا تدريجيا لمده 
-reyemsroKالتحرر الحديد مطابق لنظام  انتظاموجدنا  ،عند تحميل نتائج تحرر الحديد
يضا من نتائج أو  ،خلانتفال القابمة المبممرات. والذي يصف تحرر الدواء من بين ledoMsappeP
كل ىذا يدعم  ،الحبات تنتفخ و لكن تبدأ بالتفتت بمرحمو لاحقو أنفحص كميات دخول الماء وجدنا 
ومن ثم بمساعده تفتت البوليمر في وقت  بدايةبنظام الانتشار  الحبةالحديد يخرج من   إنو نظري
 لاحق.
وتقوم  طويمة لفترة المعدةفي  ثابتةيد تبقى استطعنا تشكيل حبوب من الحد الدراسةفي ىذه  بالمحصمة
 امتصاص الحديد. زيادةىذا النوع من الحبات يمكن ان يكون لو اثر كبير في  ،بتحرير الحديد تدريجيا
امتصاص  زيادةدراسات سريريو عمى ىذه الحبات لفحص مدى فعاليتيا في  بإجراءوفي الختام نوصي 
 الحديد عند المرضى.
